WO2007044907A2 - Vascular sheath with variable lumen construction - Google Patents
Vascular sheath with variable lumen construction Download PDFInfo
- Publication number
- WO2007044907A2 WO2007044907A2 PCT/US2006/040094 US2006040094W WO2007044907A2 WO 2007044907 A2 WO2007044907 A2 WO 2007044907A2 US 2006040094 W US2006040094 W US 2006040094W WO 2007044907 A2 WO2007044907 A2 WO 2007044907A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- renal
- catheter
- peripheral
- lumen
- introducer sheath
- Prior art date
Links
- 238000010276 construction Methods 0.000 title description 8
- 230000002792 vascular Effects 0.000 title description 5
- 230000002093 peripheral effect Effects 0.000 claims abstract description 151
- 238000011282 treatment Methods 0.000 claims abstract description 134
- 238000000034 method Methods 0.000 claims abstract description 80
- 210000003090 iliac artery Anatomy 0.000 claims abstract description 28
- 210000001105 femoral artery Anatomy 0.000 claims abstract description 22
- 238000003780 insertion Methods 0.000 claims abstract description 19
- 230000037431 insertion Effects 0.000 claims abstract description 19
- 210000002254 renal artery Anatomy 0.000 claims description 74
- 210000001367 artery Anatomy 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 35
- 210000003734 kidney Anatomy 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 238000001802 infusion Methods 0.000 claims description 19
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 11
- 230000003907 kidney function Effects 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 8
- 238000012384 transportation and delivery Methods 0.000 description 48
- 239000003795 chemical substances by application Substances 0.000 description 44
- 239000012530 fluid Substances 0.000 description 28
- 230000007704 transition Effects 0.000 description 20
- 210000000709 aorta Anatomy 0.000 description 15
- 208000033626 Renal failure acute Diseases 0.000 description 14
- 201000011040 acute kidney failure Diseases 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 239000000975 dye Substances 0.000 description 12
- 201000003068 rheumatic fever Diseases 0.000 description 12
- 210000005227 renal system Anatomy 0.000 description 11
- 206010007559 Cardiac failure congestive Diseases 0.000 description 10
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 238000002583 angiography Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000001010 compromised effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000702 aorta abdominal Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000011477 surgical intervention Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 229920002614 Polyether block amide Polymers 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000994 contrast dye Substances 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000013152 interventional procedure Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- CVKUMNRCIJMVAR-UHFFFAOYSA-N Fenoldopam mesylate Chemical compound CS(O)(=O)=O.C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 CVKUMNRCIJMVAR-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 238000002589 cardiac ventriculography Methods 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 229960004009 fenoldopam mesylate Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000002996 urinary tract agent Substances 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
- A61M25/0668—Guide tubes splittable, tear apart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2002/065—Y-shaped blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M2025/0024—Expandable catheters or sheaths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M2025/0183—Rapid exchange or monorail catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M2025/0188—Introducing, guiding, advancing, emplacing or holding catheters having slitted or breakaway lumens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
- A61M2025/0681—Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
Definitions
- Embodiments of the present invention relate to the field of medical devices, and more particularly to a system and method for locally delivering fluids or agents within the body of a patient. Still more particularly, it relates to a system and method for locally delivering fluids or agents into branch blood vessels or body lumens from a main vessel or lumen, respectively, and in particular into renal arteries extending from an aorta in a patient.
- Local “fluid" delivery systems may include drugs or other agents, or may even include locally delivering the body's own fluids, such as artificially enhanced blood transport (e.g. either entirely within the body such as directing or shunting blood from one place to another, or in extracorporeal modes such as via external blood pumps etc.).
- artificially enhanced blood transport e.g. either entirely within the body such as directing or shunting blood from one place to another, or in extracorporeal modes such as via external blood pumps etc.
- Local “agent” delivery systems are herein generally intended to relate to introduction of a foreign composition as an agent into the body, which may include drug or other useful or active agent, and may be in a fluid form or other form such as gels, solids, powders, gases, etc. It is to be understood that reference to only one of the terms fluid, drug, or agent with respect to local delivery descriptions may be made variously in this disclosure for illustrative purposes, but is not generally intended to be exclusive or omissive of the others; they are to be considered interchangeable where appropriate according to one of ordinary skill unless specifically described to be otherwise.
- local agent delivery systems and methods are often used for the benefit of achieving relatively high, localized concentrations of agent where injected within the body in order to maximize the intended effects there and while minimizing unintended peripheral effects of the agent elsewhere in the body.
- a particular dose of a locally delivered agent may be efficacious for an intended local effect
- the same dose systemically delivered would be substantially diluted throughout the body before reaching the same location.
- the agent's intended local effect is equally diluted and efficacy is compromised.
- systemic agent delivery requires higher dosing to achieve the required localized dose for efficacy, often resulting in compromised safety due to for example systemic reactions or side effects of the agent as it is delivered and processed elsewhere throughout the body other than at the intended target.
- Angiography is one such practice using a hollow, tubular angiography catheter for locally injecting radiopaque dye into a blood chamber or vessel, such as for example coronary arteries in the case of coronary angiography, or in a ventricle in the case of cardiac ventriculography.
- angiographic catheters of the type just described above, and other similar tubular delivery catheters have also been disclosed for use in locally injecting treatment agents through their delivery lumens into such body spaces within the body. More detailed examples of this type include local delivery of thrombolytic drugs such as TP ATM, heparin, cumadin, or urokinase into areas of existing clot or thrombogenic implants or vascular injury.
- thrombolytic drugs such as TP ATM, heparin, cumadin, or urokinase into areas of existing clot or thrombogenic implants or vascular injury.
- various balloon catheter systems have also been disclosed for local administration of therapeutic agents into target body lumens or spaces, and in particular associated with blood vessels.
- balloons with porous or perforated walls that elute drug agents through the balloon wall and into surrounding tissue such as blood vessel walls.
- localized delivery of therapeutic agents include various multiple balloon catheters that have spaced balloons that are inflated to engage a lumen or vessel wall in order to isolate the intermediate catheter region from in-flow or out- flow across the balloons.
- a fluid agent delivery system is often coupled to this intermediate region in order to fill the region with agent such as drug that provides an intended effect at the isolated region between the balloons.
- Acute renal failure is an abrupt decrease in the kidney's ability to excrete waste from a patient's blood. This change in kidney function may be attributable to many causes.
- a traumatic event such as hemorrhage, gastrointestinal fluid loss, or renal fluid loss without proper fluid replacement may cause the patient to go into ARF. Patients may also become vulnerable to ARF after receiving anesthesia, surgery, or a-adrenergic agonists because of related systemic or renal vasoconstriction.
- systemic vasodilation caused by anaphylaxis, and anti-hypertensive drugs, sepsis or drug overdose may also cause ARF because the body's natural defense is to shut down, i.e., vasoconstriction of nonessential organs such as the kidneys.
- Reduced cardiac output caused by cardiogenic shock, congestive heart failure, pericardial tamponade or massive pulmonary embolism creates an excess of fluid in the body, which can exacerbate congestive heart failure.
- a reduction in blood flow and blood pressure in the kidneys due to reduced cardiac output can in turn result in the retention of excess fluid in the patient's body, leading, for example, to pulmonary and systemic edema.
- Previously known methods of treating ARF, or of treating acute renal insufficiency associated with congestive heart failure (“CHF”) involve administering drugs.
- drugs that have been used for this purpose include, without limitation: vasodilators, including for example papaverine, fenoldopam mesylate, calcium channel blockers, atrial natriuretic peptide (ANP), acetylcholine, nifedipine, nitroglycerine, nitroprusside, adenosine, dopamine, and theophylline; antioxidants, such as for example acetylcysteine; and diuretics, such as for example mannitol, or furosemide.
- vasodilators including for example papaverine, fenoldopam mesylate, calcium channel blockers, atrial natriuretic peptide (ANP), acetylcholine, nifedipine, nitroglycerine, nitroprusside
- the renal system in many patients may also suffer from a particular fragility, or otherwise general exposure, to potentially harmful effects of other medical device interventions.
- the kidneys as one of the body's main blood filtering tools may suffer damage from exposed to high-density radiopaque contrast dye, such as during coronary, cardiac, or neuro angiography procedures.
- radiocontrast nephropathy or “RCN” is often observed during such procedures, wherein an acute impairment of renal function follows exposure to such radiographic contrast materials, typically resulting in a rise in serum creatinine levels of more than 25% above baseline, or an absolute rise of 0.5 mg/dl within 48 hours.
- kidney damage associated with RCN is also a frequently observed cause of ARF.
- the kidneys' function is directly related to cardiac output and related blood pressure into the renal system.
- These physiological parameters may also be significantly compromised during a surgical intervention such as an angioplasty, coronary artery bypass, valve repair or replacement, or other cardiac interventional procedure.
- the various drugs used to treat patients experiencing ARF associated with other conditions such as CHF have also been used to treat patients afflicted with ARF as a result of RCN.
- Such drugs would also provide substantial benefit for treating or preventing ARF associated with acutely compromised hemodynamics to the renal system, such as during surgical interventions.
- a Seldinger access technique to the femoral artery involves relatively controlled dilation of a puncture hole to minimize the size of the intruding window through the artery wall, and is a preferred method where the profiles of such delivery systems are sufficiently small. Otherwise, for larger systems a "cut-down" technique is used involving a larger, surgically made access window through the artery wall.
- a local renal agent delivery system for contemporaneous use with other retrogradedly delivered medical device systems, such as of the types just described above, would preferably be adapted to allow for such interventional device systems, in particular of the types and dimensions just described, to pass upstream across the renal artery ostia (a) while the agent is being locally delivered into the renal arteries, and (b) while allowing blood to flow downstream across the renal artery ostia, and (c) in an overall cooperating system that allows for Seldinger femoral artery access.
- Each one of these features (a), (b), or (c), or any sub-combination thereof, would provide significant value to patient treatment; a local renal delivery system providing for the combination of all three features is so much the more valuable.
- the renal arteries extend from respective ostia along the abdominal aorta that are significantly spaced apart from each other circumferentially around the relatively very large aorta. Often, these renal artery ostia are also spaced from each other longitudinally along the aorta with relative superior and inferior locations. This presents a unique challenge to locally deliver drugs or other agents into the renal system on the whole, which requires both kidneys to be fed through these separate respective arteries via their uniquely positioned and substantially spaced apart ostia. This becomes particularly important where both kidneys may be equally at risk, or are equally compromised, during an invasive upstream procedure - or, of course, for any other indication where both kidneys require local drug delivery.
- an appropriate local renal delivery system for such indications would preferably be adapted to feed multiple renal arteries perfusing both kidneys.
- mere local delivery of an agent into the natural, physiologic blood flow path of the aorta upstream of the kidneys may provide some beneficial, localized renal delivery versus other systemic delivery methods, but various undesirable results still arise.
- the high flow aorta immediately washes much of the delivered agent beyond the intended renal artery ostia. This reduces the amount of agent actually perfusing the renal arteries with reduced efficacy, and thus also produces unwanted loss of the agent into other organs and tissues in the systemic circulation (with highest concentrations directly flowing into downstream circulation).
- tubular local delivery catheters such as angiographic catheters, other "end-hole” catheters, or otherwise, may be positioned with their distal agent perfusion ports located within the renal arteries themselves for delivering agents there, such as via a percutaneous translumenal procedure via the femoral arteries (or from other access points such as brachial arteries, etc.).
- angiographic catheters such as angiographic catheters, other "end-hole" catheters, or otherwise
- distal agent perfusion ports located within the renal arteries themselves for delivering agents there, such as via a percutaneous translumenal procedure via the femoral arteries (or from other access points such as brachial arteries, etc.).
- angiographic catheters such as angiographic catheters, other "end-hole" catheters, or otherwise
- distal agent perfusion ports located within the renal arteries themselves for delivering agents there, such as via a percutaneous translumenal procedure via the femoral arteries (or from other access points such as brachi
- the renal arteries themselves may have pre-existing conditions that either prevent the ability to provide the required catheter seating, or that increase the risks associated with such mechanical intrusion.
- the artery wall may be diseased or stenotic, such as due to atherosclerotic plaque, clot, dissection, or other injury or condition.
- IABPs intra-aortic balloon pumps
- One such technique involves placing an IABP in the abdominal aorta so that the balloon is situated slightly below (proximal to) the branch arteries.
- the balloon is selectively inflated and deflated in a counterpulsation mode (by reference to the physiologic pressure cycle) so that increased pressure distal to the balloon directs a greater portion of blood flow into principally the branch arteries in the region of their ostia.
- an ability to locally deliver such dye into the renal artery from within the artery itself, such as by seating an angiography catheter there, may also be hindered by the same stenotic condition requiring the dye injection in the first place (as introduced above).
- patients may have stent-grafts that may prevent delivery catheter seating.
- a local renal drug delivery system and at least one adjunctive distal interventional device, such as an angiographic or guiding catheter, through a single access site, such as a single femoral arterial puncture.
- the present invention provides treatment delivery systems that facilitate a single stick entry for renal infusion during peripheral vascular interventional procedures.
- Improved introducer sheaths or main outer delivery sheaths channel passage of both renal and peripheral catheter systems.
- embodiments provide introducer sheaths having exit port designs that allow passage of catheters and other treatment devices.
- Improved back, proximal, or workspace ends of treatment systems are also provided.
- inventions of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery.
- the system includes a renal catheter, a peripheral catheter, and an introducer sheath having a first lumen and a second lumen.
- the first lumen can be configured to receive the renal catheter and can be sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch.
- the second lumen can be configured to receive the peripheral catheter and can be sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch.
- the introducer sheath may include an exit port in communication with the first lumen.
- the introducer sheath may also include a proximal section, a distal section, a tapered section therebetween having an exit port.
- the introducer sheath includes a coil disposed at the proximal section, the distal section, and the tapered section. The coil can have a first pitch at the proximal and distal sections and a second pitch at the tapered section.
- the exit port includes a plug having a slit.
- the system includes a drug infusion source in operative association with the renal catheter.
- inventions of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery.
- the system can include a renal catheter having a distal bifurcation, a peripheral catheter, and an introducer sheath having a first lumen and a second lumen.
- the first lumen can be configured to receive the renal catheter and can be separated from the second lumen by a flexible separator flap.
- the second lumen can be configured to receive the peripheral catheter.
- at least one of the first lumen and the second lumen includes a variable cross-section.
- the introducer sheath may include an exit port in communication with the first lumen.
- the introducer sheath may also include a proximal section, a distal section, and a tapered section therebetween having an exit port.
- the introducer sheath may include a coil disposed at the proximal section, the distal section, and the tapered section.
- the coil can have a first pitch at the proximal and distal sections and a second pitch at the tapered section, hi some cases, the system includes a drug source in operative association with the renal catheter.
- embodiments of the present invention provide a method of delivering treatment to a renal artery and a peripheral artery.
- the method can include positioning an introducer sheath in an iliac artery, advancing a renal catheter through a first lumen of the introducer sheath to a location at or near the renal artery, and advancing a peripheral catheter through a second lumen of the introducer sheath to a location at or near the peripheral artery.
- the first lumen and the second lumen of the introducer sheath can be separated by a flexible separator flap.
- at least one of the first lumen and the second lumen includes a variable cross-section.
- the method may also include advancing the renal catheter through an exit port of the introducer sheath, where the exit port is in communication with the first lumen, hi some cases, the method also includes providing a renal treatment via the renal catheter, and providing a peripheral treatment via the peripheral catheter.
- the method may include delivering a renal therapeutic agent via the renal catheter, where the renal therapeutic agent improves kidney function, prevents kidney damage, or both.
- embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery.
- the system can include, for example, a renal catheter, a peripheral catheter, and an introducer sheath having an exit port.
- the introducer sheath can be configured to receive the renal catheter and the peripheral catheter and can be sized to extend from a patient insertion site past a femoral or iliac artery location near or distal to a patient aortic branch to an opposite femoral or iliac artery location near or distal to the patient aortic branch, such that when the introducer sheath is placed in the patient, the exit port is situated at or near the a femoral or iliac artery location near or distal to the patient aortic branch, m some cases, the introducer sheath includes a proximal section, a distal section, and a tapered section therebetween. The exit port may be disposed at the tapered section.
- the introducer sheath may also include a coil disposed at the proximal section, the distal section, and the tapered section.
- the coil can have a first pitch at the proximal and distal sections and a second pitch at the tapered section.
- the renal catheter may include a bifurcated distal end.
- embodiments of the present invention include a method of positioning a renal treatment system and a peripheral treatment system.
- the method may include positioning an introducer sheath in an iliac artery, advancing a renal catheter of the renal treatment system through a lumen of the introducer sheath to a location at or near a renal artery, and advancing a peripheral catheter of the peripheral treatment system through the lumen of the introducer sheath to a location at or near a peripheral artery.
- the method may also include advancing the renal catheter through an exit port of the introducer sheath.
- the exit port can be located proximal to a distal end of the introducer sheath.
- the method includes providing a renal treatment via the renal catheter, and providing a peripheral treatment via the peripheral catheter.
- the method can include delivering a renal therapeutic agent via the renal catheter, where the renal therapeutic agent improves kidney function, prevents kidney damage, or both.
- inventions of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery.
- the system can include, for example, a plurality of renal catheters, a plurality of peripheral catheters, and an introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens.
- Each of the plurality of renal catheter lumens can be configured to receive at least one of the plurality of renal catheters and can be sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch.
- Each of the plurality of peripheral catheter lumens can be sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch.
- each of the plurality of renal catheter lumens and peripheral catheter lumens exit the introducer sheath at distinct locations along a length of the sheath.
- at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section.
- embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery.
- the system includes a plurality of renal catheters, a plurality of peripheral catheters, and an introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens.
- At least one of the renal catheters may include a distal bifurcation.
- Each of the plurality of renal catheter lumens can be configured to receive at least one of the plurality of renal catheters.
- Each of the plurality of peripheral catheter lumens can be configured to receive at least one of the plurality of peripheral catheters, hi some cases, at least one of the renal catheter lumens is separated from at least one of the peripheral catheter lumens by a flexible separator flap.
- Each of the plurality of renal catheter lumens and peripheral catheter lumens may exit the introducer sheath at distinct locations along a length of the sheath, hi some cases, at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens includes a variable cross-section.
- embodiments of the present invention include a method of delivering treatment to a renal artery and a peripheral artery.
- the method may include, for example, positioning an introducer sheath in an iliac artery, where the introducer sheath includes a plurality of renal catheter lumens and a plurality of peripheral catheter lumens.
- the method may also include advancing each of a plurality of renal catheters through a respective renal catheter lumen of the plurality of renal catheter lumens to a location at or near the renal artery.
- the method may include advancing each of a plurality of peripheral catheters through a respective peripheral catheter lumen of the plurality of peripheral catheter lumens to a location at or near the peripheral artery, hi some cases, at least one of the renal catheter lumens is separated from at least one of the peripheral catheter lumens by a flexible separator flap.
- Each of the plurality of renal catheter lumens and peripheral catheter lumens may exit the introducer sheath at distinct locations along a length of the sheath, hi some cases, at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section.
- the method may include providing a renal treatment via at least one of the plurality of renal catheters, providing a peripheral treatment via at least one of the plurality of peripheral catheters, or both.
- the method may include delivering a renal therapeutic agent via at least one of the plurality of renal catheters.
- the renal therapeutic agent may improve kidney function, prevent kidney damage, or both.
- FIGS. IA-I C illustrate a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
- FIG. 2 illustrates a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
- FIG. 3 depicts an introducer sheath according to embodiments of the present invention.
- FIG. 4 depicts an introducer sheath according to embodiments of the present invention.
- FIG. 5 depicts an introducer sheath according to embodiments of the present invention.
- FIG. 6 depicts an introducer sheath according to embodiments of the present invention.
- FIG. 7 depicts an introducer sheath according to embodiments of the present invention.
- FIG. 8 depicts a renal catheter according to embodiments of the present invention.
- FIG. 9 depicts a Y-hub assembly according to embodiments of the present invention.
- FIG. 10 depicts a treatment sheath according to embodiments of the present invention.
- FIG. 11 depicts a treatment sheath according to embodiments of the present invention.
- FIG. 12 depicts a treatment sheath according to embodiments of the present invention.
- FIG. 13 illustrates a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
- FIG. 14 illustrates a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
- FIGS. 15-15C depict an introducer sheath according to embodiments of the present invention.
- FIGS. 16A-16C illustrates an exemplary method of using system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
- a treatment sheath can be delivered over a guidewire through an introducer or main outer sheath to a site of renal artery cannulation. Once the guidewire is removed, the treatment catheter can be delivered through the treatment sheath. Upon delivery and deployment of the catheter branches, the treatment sheath can be retracted from the body to allow space for passage of the device used in peripheral intervention.
- FIG. IA shows a system 100 for delivering treatment to a renal artery 10 and a peripheral artery 20 of a patient according to embodiments of the present invention.
- a peripheral artery may encompass, for example, an iliac artery 30, a femoral artery 40, and the like.
- System 100 includes a renal treatment system having a renal catheter 110, a peripheral treatment system having a peripheral catheter 120, and an introducer sheath 130.
- a renal treatment system includes a renal treatment sheath.
- a peripheral treatment system can include a peripheral treatment sheath.
- introducer sheath extends from an insertion point 50 to an aortic bifurcation 60.
- Renal catheter 110 and peripheral catheter 120 can each exit introducer sheath 130 laterally and navigate toward their own respective delivery site
- renal catheter 110 can exit introducer sheath 130 and travel through aorta 70 to the renal arteries 10.
- an introducer sheath 130' can have a first lumen
- FIG. 1C depicts an introducer sheath 130" having a single lumen 136" configured to receive a renal catheter 110" and a peripheral catheter 120".
- an introducer sheath can be sized to extend from an insertion point to an opening in the iliac artery.
- an introducer sheath can be sized to extend from an insertion point to an aortic bifurcation.
- System 200 includes a renal catheter 210, a peripheral catheter 220, and an introducer sheath 230.
- Introducer sheath extends from an insertion point 205 across an aortic bifurcation 206 to a peripheral artery 202, which may be an iliac artery 203 or a femoral artery 204.
- Renal catheter 210 and peripheral catheter 220 can each exit introducer sheath 230 laterally and navigate toward their own respective delivery site.
- Introducer sheath 230 includes a first portion 232 configured to receive renal catheter 210 and peripheral catheter 220, and a second portion 234 configured to receive peripheral catheter 220. Introducer sheath also includes an exit port 236 through which renal catheter 210 can pass. Often, first portion 232 has a larger diameter than second portion 234. In some embodiments, renal catheter 210 has an outer diameter of about 1.5F and peripheral intervention system has an outer diameter or equivalent thereof of about 8F. Introducer sheath 230 passes through a first iliac artery and extends to curve toward the opposite iliac artery, which can facilitate a convenient navigation of the peripheral system. Exit port 236 may be disposed anywhere along the length of introducer sheath 230.
- exit port 236 is disposed at a location proximal to a distal exit 238 of sheath 230. Exit port 236 allows renal catheter 210 to exit introducer sheath 230 at or near aortic bifurcation 206.
- FIG. 3 depicts an introducer sheath 330 having a proximal portion 332 and a distal portion 334.
- Proximal portion is coupled with a Y-hub 331.
- proximal portion 332 can have an inner diameter within a range from about 9.5F to about 1OF
- distal portion 334 can have an inner diameter within a range from about 8F to about 8.5F.
- proximal portion 332 can have an inner diameter within a range from about 7.5F to about 12F
- distal portion 334 can have an inner diameter within a range from about 5.5F to about 9.5F.
- proximal portion 332 can have an inner diameter of about 8F
- distal portion 334 can have an inner diameter of about 7F
- Introducer sheath 330 also includes an exit port 336 disposed at a transition portion 337 situated between proximal portion 332 and distal portion 334.
- Exit port 336 can include an open aperture sized to receive elements of a treatment system, such as a catheter or a sheath.
- an introducer sheath 430 may include a coiling or coil 440.
- a coil provides structural reinforcement to an introducer sheath.
- Introducer sheath 430 includes a first proximal portion 432, a second distal portion 434, and a transition portion 437 disposed therebetween.
- Transition portion 437 often defines a tapered shape or profile and includes an exit port 436.
- coil 440 includes a first portion 442, a second portion 444, and a transition portion 447 disposed therebetween.
- coil 440 is wrapped at a first pitch at first portion 442 and second portion 444, and is wrapped at a second pitch at transition portion 447.
- the second pitch at transition portion 447 can be spaced sufficiently to allow enough space for exit port 436 to provide an aperture or opening in introducer sheath 430 without piercing the coil or traversing the path of the coil. Accordingly, the exit port can be created without disturbing the continuity of the coil, hi some cases, the transition portion 447 reflects a jump in the coil pitch for one full wrap. Coils may be disposed on an outside layer of the introducer sheath, on an inside layer of the introducer sheath, or on an intermediate layer of the introducer sheath.
- an introducer sheath may include a coil layer disposed only distal to the transition portion.
- FIG. 5 illustrates an introducer sheath 530 having a first portion 532, a second portion 534, and a tapered transition portion 537 disposed therebetween. Transition portion 537 may present an exit port 536.
- Introducer sheath 530 also includes a coil 540 disposed at or near second portion 534. m some cases, the wall thickness of first portion 532 may be greater than the wall thickness of second portion 534, as compensation for the torquability on the proximal and wider end of the first portion of the introducer sheath. Such configurations can help maintain a uniform or desired torquing profile along the length of introducer sheath 530.
- an exit port can have an open aperture through which a renal catheter or treatment sheath can pass.
- the exit port may or may not include a covering or plug.
- an introducer sheath 630 can include a proximal portion 632, a distal portion 634, and a transition portion 637 disposed therebetween.
- Transition portion 637 includes an exit port 636 having a plug 636a with a passage slit 636b.
- plug 636a includes an elastomeric material such as silicone. Plug 636a can be formed in contour with the overall surface profile of the introducer sheath.
- Passage slit 636b can be sized to allow passage of elements of a renal treatment system, such as a renal treatment sheath or a renal catheter.
- FIG. 7 shows an introducer sheath 730 a proximal portion 732, a distal portion 734, and a transition portion 737 disposed therebetween.
- Transition portion 737 includes an exit port 736 having a plug 736a with a passage slit 736b.
- Plug 736a can be formed in contour with the overall surface profile of the introducer sheath.
- Passage slit 736b can be sized to allow passage of a renal catheter.
- plug 736a includes one or more layers of elastomeric material.
- plug 736a may include an inner layer 736c and an outer layer 736d.
- plug 736a includes an embedded inner silicone layer and an outer layer of low-durometer Pebax ® covering the entire section circumferentially to aid in supporting the integrity of plug 736a.
- FIG. 13 shows a system 1300 for delivering treatment to a renal artery and a peripheral artery.
- System 1300 includes a renal catheter 1310 and a peripheral catheter 1320.
- Renal catheter 1310 may include a proximal section 1312 disposed exterior to the patient's body, and a distal section 1314 disposed interior to the patient's body.
- Proximal section 1312 presents an extended or lengthened workable catheter length.
- renal catheter 1310 includes a proximal section 1312 having a 1.5F NiTi section and a distal section 1314 having a 2-4F Pebax ® section.
- the diameter of distal section 1314 can be selected so as to provide certain desired characteristics.
- the distal section diameter can be selected to allow for decreased mechanical resistance to flow and for desired handling characteristics when a clinician or operator rolls or spools the workable length.
- FIG. 9 illustrates an exemplary Y-hub 931 and introducer sheath 930 combination, wherein Y-hub is coupled with a proximal end 932 of introducer sheath 930.
- Y-hub 931 permits the entry of a renal treatment system and a peripheral treatment system therethrough.
- Y-hub can also act, often simultaneously, to allow infusion of a fluid through a separate sub-port 931a.
- sub-port 931a is in operative association with a Y-hub branch that receives a renal catheter.
- sub-port 93 Ia can be in operative association with a Y-hub branch that receives a peripheral catheter.
- a Y-hub may include such a sub-port on both Y-hub branches.
- Sub-port 93 Ia can be coupled or in fluid communication with an infusion pump 980, and can enter Y-hub 930 at an infusion insertion section thereof.
- Infusion insertion section 985 can be disposed or isolated within the Y-hub branch between two plugs 986.
- catheter 910 includes perforations or apertures 913 that allow passage of infusion fluid from sub-port 931a into catheter 910.
- a sub-port can be connected with an infusion pump, and can enter a renal catheter entry lumen of a Y-hub at a section that is isolated by two plugs.
- the plugs may allow for selective passage of a catheter or treatment sheath, but inhibit passage of fluids under certain pressures.
- the plugs may allow for the passage of a catheter or treatment sheath, but may prevent passage of a fluid that is pressurized at 20psi or less.
- a catheter can include perforations configured for alignment between the two plugs, such that fluid supplied by a infusion pump can pressurize in a sub-chamber or infusion insertion section between the two plugs and enter the catheter through the perforations.
- Embodiments such as these allow for the infusion of fluid into a catheter while also permitting removal and reentry of a treatment sheath for both delivery and recapture of a treatment catheter and any branches or devices attached thereto.
- FIG. 14 illustrates an exemplary back-end interface having a Y-hub 1431 in combination with an introducer sheath 1430, wherein Y-hub is coupled with a proximal end 1432 of introducer sheath 1430.
- Y-hub 1431 permits the entry of a renal treatment system 1410 and a peripheral treatment or intervention system 1420 therethrough.
- Renal treatment system 1410 may include a needle pierce section 1415 adapted to receive a needle 1417, which may be coupled with an infusion source 1482. Needle pierce section 1415 can be disposed along the renal treatment system at a location where the renal treatment system exits the patient's body.
- introducer sheath 1430 can be delivered having an infusion pump 1480 connected or in fluid communication with a proximal end of the renal treatment system or catheter.
- the renal catheter can be disconnected at a proximal end from infusion pump 1480, and infusion can resume or continue from needle pierce section 1415.
- Renal treatment system 1410 may include a proximal catheter 1412 that includes a NiTi shaft.
- Other back-end interface solutions include treatment sheaths that can be removed from a catheter via a longitudinal dissection configuration.
- FIG. 12 shows a proximal portion 1232 of a treatment sheath 1230.
- Proximal portion 1232 may include a pierce groove 1232a and a tear-away grip 1332b. With this peel-away configuration, when a treatment sheath is retrieved it can be easily removed. As desired, a peel-away configuration may or may not be used on conjunction with a catheter having an extended or lengthened workable catheter length.
- FIG. 10 illustrates an treatment sheath 1030 having a longitudinal clip section 1030a that can be clipped off from and reclipped on to a catheter line. In some cases, longitudinal clip section presents a continuous clip along the length of treatment sheath 1030.
- FIG. 11 illustrates a treatment sheath 1130 having an array of serially arranged sheath sections 1130a having clips 1130b, where sheath sections 1130a are held in place by a supporting structure such as a wire 1130c.
- Another back-end interface solution includes a catheter connector.
- renal treatment system 810 includes a catheter connector 819 than can allow disconnection and reconnection of a catheter proximal section 812 and a catheter distal section 814.
- Such disconnection and reconnection of the catheter line can provide for facile removal of a treatment sheath.
- such a configuration may or may not be used on conjunction with a catheter having an extended or lengthened workable catheter length.
- an intervention system may include an introducer sheath with variable lumen construction that has the ability to serve asynchronously or synchronously as a conduit for multiple devices.
- Many traditional sheaths and catheters are constructed with a single lumen.
- Multi lumen catheters are also common (such as balloon catheters) and multi-lumen sheaths have likewise been described in, for example, U.S. Patent 4,769,005 and U.S. Patent Application No. 11/073,421 filed March 4, 2005, the entire disclosures of which are hereby incorporated by reference for all purposes.
- the present sheath may differ from known sheaths in that it can be designed to handle multiple products through its multiple lumens either simultaneously and/or at different times, and can be adapted with variable luminal cross sections to allow for passage of devices of multiple larger sizes through different lumens at different times during a given procedure.
- a dual lumen or multiple lumen design can provide the advantages of separating the multiple devices to reduce the propensity for tangling and also allows fluid separation between the lumens to allow for more selective infusions if desired.
- the present sheath has multiple lumens with varying points of exit from the sheath designed to allow passage of multiple devices to remote regions of the vasculature simultaneously or at different times during the same procedure.
- a sheath can have an outer diameter (OD) similar to that of a standard, commercially available 1OF vascular introducer sheath.
- OD outer diameter
- two devices with crossing profiles of about 8F can pass through either lumen at different times, or, alternatively, a device up to 8F can pass through one lumen simultaneously with a device of up to about 2F in the other lumen. Combinations between these extremes are also contemplated (e.g., two 5F devices simultaneously).
- the present sheath can be constructed using a flexible and lubricious separator between the two luminal spaces, which can be easily displaced as needed when devices are passed.
- this device can have application in the same setting as devices as described in previously incorporated U.S. Provisional Patent Application Nos. 60/725,756 filed October 11, 2005 and 60/742,579 filed December 5, 2005.
- the sheath can be constructed with a dedicated 2-lumen hub, each lumen feeding into a separate lumen of the sheath.
- the sheath can taper to the desired diameter (1OF in this example) with the separator flap creating the two lumens.
- Introducer sheath 1530 includes a proximal section 1532, a distal section 1534, and a tapered transition section 1537 disposed therebetween, as depicted in FIG. 15. Transition section 1537 includes an exit port 1536. Introducer sheath 1530 also includes a first lumen 1530a configured to receive renal treatment system and a second lumen 1530b configured to receive a peripheral treatment system. Proximal section 1532 and transition section 1537 include a separator 1530c that divides first lumen 1530a and second lumen 1530b.
- Distal section 1534 includes a single lumen construction, as shown in FIG. 15A.
- Transition section 1537 includes a dual lumen construction with variable luminal cross- section, as shown in FIG. 15B.
- the cross sections of the first and second lumens may vary by movement of the wall separating the two lumens.
- Proximal section 1532 includes a dual lumen construction, where both lumens are "full size" to facilitate device entry, as shown in FIG. 15C.
- separator 1530c includes a flexible separator flap.
- a treatment sheath can be delivered over a guidewire through an introducer or main outer sheath to a site of renal artery cannulation. Once the guidewire is removed, the treatment catheter can be delivered through the treatment sheath. Upon delivery and deployment of the catheter, the treatment sheath can be retracted from the body to allow space for passage of a sheath used in a peripheral intervention.
- a treatment system 1600 can include an introducer sheath 1630, a renal treatment system 1610, and a peripheral treatment system 1620. Introducer sheath 1630 includes a proximal section 1632, a distal section 1634, and a transition section 1637 disposed therebetween.
- Transition section 1637 includes an exit port 1636.
- Introducer sheath 1630 also includes a flexible or stretchable separator 1631 that divides a first lumen 1633 from a second lumen 1635. Because separator 1631 is flexible, stretchable, or otherwise deformable, separator 1631 can move so as to allow variability in the interior dimensions of first lumen 1633 and second lumen 1635. Accordingly, first lumen 1633 and second lumen 1635 can be referred to as variable lumens, or as lumens having variable cross- sections or profiles.
- Renal treatment system 1610 can include a renal treatment sheath 1612, a renal catheter 1614 having a bifurcated distal end 1616, and a renal sheath guidewire 1618.
- Peripheral treatment system 1620 can include a peripheral treatment sheath 1622, a peripheral catheter 1624, and a peripheral sheath guidewire 1628.
- FIG. 16A illustrates a method step that involves advancing renal treatment sheath 1612 along a renal sheath guidewire 1618 toward a renal treatment location.
- Renal treatment sheath 1612 passes through first lumen 1633 of the proximal section 1632 of introducer sheath 1630, and out of exit port 1636.
- Renal catheter 1614 is advanced through or housed within the interior of renal treatment sheath 1612 in a constrained or undeployed configuration.
- the section of separator 1631 that is within proximal section 1632 is flexed, stretched, or otherwise displaced, so as to accommodate renal treatment sheath 1612.
- FIG. 16B illustrates a method step that encompasses retracting renal treatment sheath 1612 and deploying bifurcated distal end 116 of renal catheter 1614. Thereafter, renal treatment sheath 1612 can be removed via any of a variety of techniques as discussed elsewhere herein.
- FIG. 16C depicts a method step that involves advancing peripheral treatment sheath 1622 along a peripheral sheath guidewire 1628 toward a peripheral treatment location.
- Peripheral treatment sheath 1622 passes through second lumen 1635 of the proximal section 1632 and distal section 1634 of introducer sheath 1630, and out of distal port 1639.
- Peripheral catheter 1624 is advanced through or housed within the interior of peripheral treatment sheath 1622.
- the section of separator 1631 that is within proximal section 1632 is flexed, stretched, or otherwise displaced, so as to accommodate peripheral treatment sheath 1622, peripheral catheter 1624, or both.
- this involves increasing the cross-section of second lumen 1635 while decreasing the cross- section of first lumen 1633.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A system for delivering a renal treatment and a peripheral treatment includes a renal catheter, a peripheral catheter, and an introducer sheath having first and second lumens. The first lumen is configured to receive the renal catheter and is sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch. The second lumen is configured to receive the peripheral catheter and is sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch. A method of delivering a renal treatment and a peripheral treatment includes positioning an introducer sheath in an iliac artery, advancing a renal catheter and a peripheral catheter through the introducer sheath, where the renal catheter is separated from the peripheral catheter within the introducer sheath by a flap.
Description
VASCULAR SHEATH WITH VARIABLE LUMEN CONSTRUCTION
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application Nos. 60/725,756 filed October 11, 2005 and 60/742,579 filed December 5, 2005, the entire contents of which are incorporated herein by reference for all purposes. This application is also related to U.S. Patent Application Nos. 11/084,738 filed March 16, 2005 and 11/241,749 filed September 29, 2005, the entire contents of which are incorporated herein by reference for all purposes.
BACKGROUND OF THE INVENTION
[0002] Embodiments of the present invention relate to the field of medical devices, and more particularly to a system and method for locally delivering fluids or agents within the body of a patient. Still more particularly, it relates to a system and method for locally delivering fluids or agents into branch blood vessels or body lumens from a main vessel or lumen, respectively, and in particular into renal arteries extending from an aorta in a patient.
[0003] Many different medical device systems and methods have been previously described for locally delivering fluids or other agents into various body regions, including body lumens such as vessels, or other body spaces such as organs or heart chambers. Local "fluid" delivery systems may include drugs or other agents, or may even include locally delivering the body's own fluids, such as artificially enhanced blood transport (e.g. either entirely within the body such as directing or shunting blood from one place to another, or in extracorporeal modes such as via external blood pumps etc.). Local "agent" delivery systems are herein generally intended to relate to introduction of a foreign composition as an agent into the body, which may include drug or other useful or active agent, and may be in a fluid form or other form such as gels, solids, powders, gases, etc. It is to be understood that reference to only one of the terms fluid, drug, or agent with respect to local delivery descriptions may be made variously in this disclosure for illustrative purposes, but is not generally intended to be exclusive or omissive of the others; they are to be considered interchangeable where appropriate according to one of ordinary skill unless specifically described to be otherwise.
[0004] In general, local agent delivery systems and methods are often used for the benefit of achieving relatively high, localized concentrations of agent where injected within the body in order to maximize the intended effects there and while minimizing unintended peripheral effects of the agent elsewhere in the body. Where a particular dose of a locally delivered agent may be efficacious for an intended local effect, the same dose systemically delivered would be substantially diluted throughout the body before reaching the same location. The agent's intended local effect is equally diluted and efficacy is compromised. Thus systemic agent delivery requires higher dosing to achieve the required localized dose for efficacy, often resulting in compromised safety due to for example systemic reactions or side effects of the agent as it is delivered and processed elsewhere throughout the body other than at the intended target.
[0005] Various diagnostic systems and procedures have been developed using local delivery of dye (e.g. radiopaque "contrast" agent) or other diagnostic agents, wherein an external monitoring system is able to gather important physiological information based upon the diagnostic agent's movement or assimilation in the body at the location of delivery and/or at other locations affected by the delivery site. Angiography is one such practice using a hollow, tubular angiography catheter for locally injecting radiopaque dye into a blood chamber or vessel, such as for example coronary arteries in the case of coronary angiography, or in a ventricle in the case of cardiac ventriculography.
[0006] Other systems and methods have been disclosed for locally delivering therapeutic agent into a particular body tissue within a patient via a body lumen. For example, angiographic catheters of the type just described above, and other similar tubular delivery catheters, have also been disclosed for use in locally injecting treatment agents through their delivery lumens into such body spaces within the body. More detailed examples of this type include local delivery of thrombolytic drugs such as TP A™, heparin, cumadin, or urokinase into areas of existing clot or thrombogenic implants or vascular injury. In addition, various balloon catheter systems have also been disclosed for local administration of therapeutic agents into target body lumens or spaces, and in particular associated with blood vessels. More specific previously disclosed of this type include balloons with porous or perforated walls that elute drug agents through the balloon wall and into surrounding tissue such as blood vessel walls. Yet further examples for localized delivery of therapeutic agents include various multiple balloon catheters that have spaced balloons that are inflated to engage a lumen or vessel wall in order to isolate the intermediate catheter region from in-flow or out-
flow across the balloons. According to these examples, a fluid agent delivery system is often coupled to this intermediate region in order to fill the region with agent such as drug that provides an intended effect at the isolated region between the balloons.
[0007] The diagnosis or treatment of many different types of medical conditions associated with various different systems, organs, and tissues, may also benefit from the ability to locally deliver fluids or agents in a controlled manner. In particular, various conditions related to the renal system would benefit a great deal from an ability to locally deliver of therapeutic, prophylactic, or diagnostic agents into the renal arteries.
[0008] Acute renal failure ("ARF") is an abrupt decrease in the kidney's ability to excrete waste from a patient's blood. This change in kidney function may be attributable to many causes. A traumatic event, such as hemorrhage, gastrointestinal fluid loss, or renal fluid loss without proper fluid replacement may cause the patient to go into ARF. Patients may also become vulnerable to ARF after receiving anesthesia, surgery, or a-adrenergic agonists because of related systemic or renal vasoconstriction. Additionally, systemic vasodilation caused by anaphylaxis, and anti-hypertensive drugs, sepsis or drug overdose may also cause ARF because the body's natural defense is to shut down, i.e., vasoconstriction of nonessential organs such as the kidneys. Reduced cardiac output caused by cardiogenic shock, congestive heart failure, pericardial tamponade or massive pulmonary embolism creates an excess of fluid in the body, which can exacerbate congestive heart failure. For example, a reduction in blood flow and blood pressure in the kidneys due to reduced cardiac output can in turn result in the retention of excess fluid in the patient's body, leading, for example, to pulmonary and systemic edema.
[0009] Previously known methods of treating ARF, or of treating acute renal insufficiency associated with congestive heart failure ("CHF"), involve administering drugs. Examples of such drugs that have been used for this purpose include, without limitation: vasodilators, including for example papaverine, fenoldopam mesylate, calcium channel blockers, atrial natriuretic peptide (ANP), acetylcholine, nifedipine, nitroglycerine, nitroprusside, adenosine, dopamine, and theophylline; antioxidants, such as for example acetylcysteine; and diuretics, such as for example mannitol, or furosemide. However, many of these drugs, when administered in systemic doses, have undesirable side effects. Additionally, many of these drugs would not be helpful in treating other causes of ARF. For example, a septic shock patient with profound systemic vasodilation often has concomitant severe renal
vasoconstriction, administering vasodilators to dilate the renal artery to a patient suffering from systemic vasodilation would compound the vasodilation system wide. In addition, for patients with severe CHF (e.g., those awaiting heart transplant), mechanical methods, such as hemodialysis or left ventricular assist devices, may be implemented. Surgical device interventions, such as hemodialysis, however, generally have not been observed to be highly efficacious for long-term management of CHF. Such interventions would also not be appropriate for many patients with strong hearts suffering from ARF.
[0010] The renal system in many patients may also suffer from a particular fragility, or otherwise general exposure, to potentially harmful effects of other medical device interventions. For example, the kidneys as one of the body's main blood filtering tools may suffer damage from exposed to high-density radiopaque contrast dye, such as during coronary, cardiac, or neuro angiography procedures. One particularly harmful condition known as "radiocontrast nephropathy" or "RCN" is often observed during such procedures, wherein an acute impairment of renal function follows exposure to such radiographic contrast materials, typically resulting in a rise in serum creatinine levels of more than 25% above baseline, or an absolute rise of 0.5 mg/dl within 48 hours. Therefore, in addition to CHF, renal damage associated with RCN is also a frequently observed cause of ARF. hi addition, the kidneys' function is directly related to cardiac output and related blood pressure into the renal system. These physiological parameters, as in the case of CHF, may also be significantly compromised during a surgical intervention such as an angioplasty, coronary artery bypass, valve repair or replacement, or other cardiac interventional procedure. Therefore, the various drugs used to treat patients experiencing ARF associated with other conditions such as CHF have also been used to treat patients afflicted with ARF as a result of RCN. Such drugs would also provide substantial benefit for treating or preventing ARF associated with acutely compromised hemodynamics to the renal system, such as during surgical interventions.
[0011] There would be great advantage therefore from an ability to locally deliver such drugs into the renal arteries, in particular when delivered contemporaneous with surgical interventions, and in particular contemporaneous with radiocontrast dye delivery. However, many such procedures are done with medical device systems, such as using guiding catheters or angiography catheters having outer dimensions typically ranging between about 4 French to about 12 French, and ranging generally between about 6 French to about 8 French in the case of guide catheter systems for delivering angioplasty or stent devices into the coronary or
neurovascular arteries (e.g. carotid arteries). These devices also are most typically delivered to their respective locations for use (e.g. coronary ostia) via a percutaneous, translumenal access in the femoral arteries and retrograde delivery upstream along the aorta past the region of the renal artery ostia. A Seldinger access technique to the femoral artery involves relatively controlled dilation of a puncture hole to minimize the size of the intruding window through the artery wall, and is a preferred method where the profiles of such delivery systems are sufficiently small. Otherwise, for larger systems a "cut-down" technique is used involving a larger, surgically made access window through the artery wall.
[0012] Accordingly, a local renal agent delivery system for contemporaneous use with other retrogradedly delivered medical device systems, such as of the types just described above, would preferably be adapted to allow for such interventional device systems, in particular of the types and dimensions just described, to pass upstream across the renal artery ostia (a) while the agent is being locally delivered into the renal arteries, and (b) while allowing blood to flow downstream across the renal artery ostia, and (c) in an overall cooperating system that allows for Seldinger femoral artery access. Each one of these features (a), (b), or (c), or any sub-combination thereof, would provide significant value to patient treatment; a local renal delivery system providing for the combination of all three features is so much the more valuable.
[0013] Notwithstanding the clear needs for and benefits that would be gained from such local drug delivery into the renal system, the ability to do so presents unique challenges as follows.
[0014] hi one regard, the renal arteries extend from respective ostia along the abdominal aorta that are significantly spaced apart from each other circumferentially around the relatively very large aorta. Often, these renal artery ostia are also spaced from each other longitudinally along the aorta with relative superior and inferior locations. This presents a unique challenge to locally deliver drugs or other agents into the renal system on the whole, which requires both kidneys to be fed through these separate respective arteries via their uniquely positioned and substantially spaced apart ostia. This becomes particularly important where both kidneys may be equally at risk, or are equally compromised, during an invasive upstream procedure - or, of course, for any other indication where both kidneys require local drug delivery. Thus, an appropriate local renal delivery system for such indications would preferably be adapted to feed multiple renal arteries perfusing both kidneys.
[0015] In another regard, mere local delivery of an agent into the natural, physiologic blood flow path of the aorta upstream of the kidneys may provide some beneficial, localized renal delivery versus other systemic delivery methods, but various undesirable results still arise. In particular, the high flow aorta immediately washes much of the delivered agent beyond the intended renal artery ostia. This reduces the amount of agent actually perfusing the renal arteries with reduced efficacy, and thus also produces unwanted loss of the agent into other organs and tissues in the systemic circulation (with highest concentrations directly flowing into downstream circulation).
[0016] In still a further regard, various known types of tubular local delivery catheters, such as angiographic catheters, other "end-hole" catheters, or otherwise, may be positioned with their distal agent perfusion ports located within the renal arteries themselves for delivering agents there, such as via a percutaneous translumenal procedure via the femoral arteries (or from other access points such as brachial arteries, etc.). However, such a technique may also provide less than completely desirable results.
[0017] For example, such seating of the delivery catheter distal tip within a renal artery may be difficult to achieve from within the large diameter/high flow aorta, and may produce harmful intimal injury within the artery. Also, where multiple kidneys must be infused with agent, multiple renal arteries must be cannulated, either sequentially with a single delivery device, or simultaneously with multiple devices. This can become unnecessarily complicated and time consuming and further compound the risk of unwanted injury from the required catheter manipulation. Moreover, multiple dye injections may be required in order to locate the renal ostia for such catheter positioning, increasing the risks associated with contrast agents on kidney function (e.g. RCN) - the very organ system to be protected by the agent delivery system in the first place. Still further, the renal arteries themselves, possibly including their ostia, may have pre-existing conditions that either prevent the ability to provide the required catheter seating, or that increase the risks associated with such mechanical intrusion. For example, the artery wall may be diseased or stenotic, such as due to atherosclerotic plaque, clot, dissection, or other injury or condition. Finally, among other additional considerations, previous disclosures have yet to describe an efficacious and safe system and method for positioning these types of local agent delivery devices at the renal arteries through a common introducer or guide sheath shared with additional medical devices used for upstream interventions, such as angiography or guide catheters. In particular, to do so concurrently with multiple delivery catheters for simultaneous infusion of multiple renal
arteries would further require a guide sheath of such significant dimensions that the preferred Seldinger vascular access technique would likely not be available, instead requiring the less desirable "cut-down" technique.
[0018] In addition to the various needs for locally delivering agents into branch arteries described above, much benefit may also be gained from simply locally enhancing blood perfusion into such branches, such as by increasing the blood pressure at their ostia. In particular, such enhancement would improve a number of medical conditions related to insufficient physiological perfusion into branch vessels, and in particular from an aorta and into its branch vessels such as the renal arteries.
[0019] Certain other approaches have provided surgical device assemblies and methods intended to enhance blood delivery into branch arteries extending from an aorta. For example, intra-aortic balloon pumps (IABPs) have been disclosed for use in diverting blood flow into certain branch arteries. One such technique involves placing an IABP in the abdominal aorta so that the balloon is situated slightly below (proximal to) the branch arteries. The balloon is selectively inflated and deflated in a counterpulsation mode (by reference to the physiologic pressure cycle) so that increased pressure distal to the balloon directs a greater portion of blood flow into principally the branch arteries in the region of their ostia. However, the flow to lower extremities downstream from such balloon system can be severely occluded during portions of this counterpulsing cycle. Moreover, such previously disclosed systems generally lack the ability to deliver drug or agent to the branch arteries while allowing continuous and substantial downstream perfusion sufficient to prevent unwanted ischemia.
[0020] It is further noted that, despite the renal risks described in relation to radiocontrast dye delivery, and in particular RCN, in certain circumstances local delivery of such dye or other diagnostic agents is indicated specifically for diagnosing the renal arteries themselves. For example, diagnosis and treatment of renal stenosis, such as due to atherosclerosis or dissection, may require dye injection into a subject renal artery. In such circumstances, enhancing the localization of the dye into the renal arteries may also be desirable. In one regard, without such localization larger volumes of dye may be required, and the dye lost into the downstream aortic flow may still be additive to impacting the kidney(s) as it circulates back there through the system. In another regard, an ability to locally deliver such dye into the renal artery from within the artery itself, such as by seating an angiography catheter there,
may also be hindered by the same stenotic condition requiring the dye injection in the first place (as introduced above). Still further, patients may have stent-grafts that may prevent delivery catheter seating.
[0021] Notwithstanding the interest and advances toward locally delivering agents for treatment or diagnosis of organs or tissues, the previously disclosed systems and methods summarized immediately above generally lack the ability to effectively deliver agents from within a main artery and locally into substantially only branch arteries extending therefrom while allowing the passage of substantial blood flow and/or other medical devices through the main artery past the branches. This is in particular the case with previously disclosed renal treatment and diagnostic devices and methods, which do not adequately provide for local delivery of agents into the renal system from a location within the aorta while allowing substantial blood flow continuously downstream past the renal ostia and/or while allowing distal medical device assemblies to be passed retrogradedly across the renal ostia for upstream use. Much benefit would be gained if agents, such as protective or therapeutic drugs or radiopaque contrast dye, could be delivered to one or both of the renal arteries in such a manner.
[0022] Several more recent advances have included local flow assemblies using tubular members of varied diameters that divide flow within an aorta adjacent to renal artery ostia into outer and inner flow paths substantially perfusing the renal artery ostia and downstream circulation, respectively. Such advances further include delivering fluid agent primarily into the outer flow path for substantially localized delivery into the renal artery ostia. These systems and methods represent exciting new developments toward localized diagnosis and treatment of pre-existing conditions associated with branch vessels from main vessels in general, and with respect to renal arteries extending from abdominal aortas in particular.
[0023] However, while these approaches in one regard provide benefit by removing the need to cannulate each renal artery of the bi-lateral renal system, substantial benefit would - still be gained conversely from a device system and method that allows for direct bi-lateral renal artery infusion without the need to deploy flow diverters or isolators into the high-flow abdominal aorta. In one particular example, patients that suffer from abdominal aortic aneurysms may not be suitable for standard delivery systems with flow diverters or isolators that are sized for normal arteries. In another regard, direct renal artery infusion allows for reduced occlusion to downstream aortic blood flow, or conversely more downstream flow
may be preserved. Still further, the ability to truly isolate drug to only the renal system, without the potential for downstream leaking or loss into the systemic circulation, may be maximized.
[0024] A need therefore still exists for improved devices and methods for locally delivering agents bi-laterally into each of two renal arteries perfusing both kidneys of a patient while a substantial portion of aortic blood flow is allowed to perfuse downstream across the location of the renal artery ostia and into the patient's lower extremities.
[0025] A need still exists for improved devices and methods for efficiently gaining percutaneous translumenal access into each side of the kidney system via their separate renal artery ostia along the abdominal aortic wall, so that procedures such as fluid agent delivery may be performed locally within both sides of the renal system.
[0026] A need still exists for improved devices and methods for locally delivering fluid agents into a renal artery from a location within the aorta of a patient adjacent the renal artery's ostium along the aorta wall.
[0027] A need still exists for improved devices and methods for locally isolating delivery of fluids or agents into the renal arteries of a patient, and while allowing other treatment or diagnostic devices and systems, such as angiographic or guiding catheter devices and related systems, to be delivered across the location.
[0028] A need still exists for improved devices and methods for locally delivering fluids or agents into the renal arteries of a patient, for prophylaxis or diagnostic procedures related to the kidneys.
[0029] A need still exists for improved devices and methods for locally isolating delivery of fluids or agents into the renal arteries of a patient in order to treat, protect, or diagnose the renal system adjunctive to performing other contemporaneous medical procedures such as angiograms other translumenal procedures upstream of the renal artery ostia.
[0030] A need still exists for improved devices and methods for delivering both a local renal drug delivery system and at least one adjunctive distal interventional device, such as an angiographic or guiding catheter, through a common delivery sheath.
[0031] A need also still exists for improved devices and methods for delivering both a local renal drug delivery system and at least one adjunctive distal interventional device, such as an
angiographic or guiding catheter, through a single access site, such as a single femoral arterial puncture.
[0032] A need also still exists for improved devices and methods for treating, and in particular preventing, ARF, and in particular relation to RCN or CHF, by locally delivering renal protective or ameliorative drugs into the renal arteries, such as contemporaneous with radiocontrast injections such as during angiography procedures.
[0033] In addition to these particular needs for selective fluid delivery into a patient's renal arteries via their ostia along the aorta, other similar needs also exist for locally isolated fluid delivery into other branch vessels or lumens extending from other main vessels or lumens, respectively, in a patient.
BRIEF SUMMARY OF THE INVENTION
[0034] The present invention provides treatment delivery systems that facilitate a single stick entry for renal infusion during peripheral vascular interventional procedures. Improved introducer sheaths or main outer delivery sheaths channel passage of both renal and peripheral catheter systems. Relatedly, embodiments provide introducer sheaths having exit port designs that allow passage of catheters and other treatment devices. Improved back, proximal, or workspace ends of treatment systems are also provided.
[0035] In a first aspect, embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery. The system includes a renal catheter, a peripheral catheter, and an introducer sheath having a first lumen and a second lumen. The first lumen can be configured to receive the renal catheter and can be sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch. The second lumen can be configured to receive the peripheral catheter and can be sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch. In some cases, at least one of the first lumen and the second lumen includes a variable cross-section. The introducer sheath may include an exit port in communication with the first lumen. The introducer sheath may also include a proximal section, a distal section, a tapered section therebetween having an exit port. In some cases, the introducer sheath includes a coil disposed at the proximal section, the distal section, and the tapered section. The coil can have a first pitch at the proximal and distal sections and a second pitch at the tapered section. In some cases, the exit port includes
a plug having a slit. In some cases, the system includes a drug infusion source in operative association with the renal catheter.
[0036] In another aspect, embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery. The system can include a renal catheter having a distal bifurcation, a peripheral catheter, and an introducer sheath having a first lumen and a second lumen. The first lumen can be configured to receive the renal catheter and can be separated from the second lumen by a flexible separator flap. The second lumen can be configured to receive the peripheral catheter. In some cases, at least one of the first lumen and the second lumen includes a variable cross-section. The introducer sheath may include an exit port in communication with the first lumen. The introducer sheath may also include a proximal section, a distal section, and a tapered section therebetween having an exit port. The introducer sheath may include a coil disposed at the proximal section, the distal section, and the tapered section. The coil can have a first pitch at the proximal and distal sections and a second pitch at the tapered section, hi some cases, the system includes a drug source in operative association with the renal catheter.
[0037] In another aspect, embodiments of the present invention provide a method of delivering treatment to a renal artery and a peripheral artery. The method can include positioning an introducer sheath in an iliac artery, advancing a renal catheter through a first lumen of the introducer sheath to a location at or near the renal artery, and advancing a peripheral catheter through a second lumen of the introducer sheath to a location at or near the peripheral artery. The first lumen and the second lumen of the introducer sheath can be separated by a flexible separator flap. In some cases, at least one of the first lumen and the second lumen includes a variable cross-section. The method may also include advancing the renal catheter through an exit port of the introducer sheath, where the exit port is in communication with the first lumen, hi some cases, the method also includes providing a renal treatment via the renal catheter, and providing a peripheral treatment via the peripheral catheter. Relatedly, the method may include delivering a renal therapeutic agent via the renal catheter, where the renal therapeutic agent improves kidney function, prevents kidney damage, or both. [0038] m still another aspect, embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery. The system can include, for example, a renal catheter, a peripheral catheter, and an introducer sheath having an exit port.
The introducer sheath can be configured to receive the renal catheter and the peripheral catheter and can be sized to extend from a patient insertion site past a femoral or iliac artery location near or distal to a patient aortic branch to an opposite femoral or iliac artery location near or distal to the patient aortic branch, such that when the introducer sheath is placed in the patient, the exit port is situated at or near the a femoral or iliac artery location near or distal to the patient aortic branch, m some cases, the introducer sheath includes a proximal section, a distal section, and a tapered section therebetween. The exit port may be disposed at the tapered section. The introducer sheath may also include a coil disposed at the proximal section, the distal section, and the tapered section. The coil can have a first pitch at the proximal and distal sections and a second pitch at the tapered section. Optionally, the renal catheter may include a bifurcated distal end.
[0039] In still another aspect, embodiments of the present invention include a method of positioning a renal treatment system and a peripheral treatment system. The method may include positioning an introducer sheath in an iliac artery, advancing a renal catheter of the renal treatment system through a lumen of the introducer sheath to a location at or near a renal artery, and advancing a peripheral catheter of the peripheral treatment system through the lumen of the introducer sheath to a location at or near a peripheral artery. The method may also include advancing the renal catheter through an exit port of the introducer sheath. The exit port can be located proximal to a distal end of the introducer sheath. In some cases, the method includes providing a renal treatment via the renal catheter, and providing a peripheral treatment via the peripheral catheter. The method can include delivering a renal therapeutic agent via the renal catheter, where the renal therapeutic agent improves kidney function, prevents kidney damage, or both.
[0040] In another aspect, embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery. The system can include, for example, a plurality of renal catheters, a plurality of peripheral catheters, and an introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens. Each of the plurality of renal catheter lumens can be configured to receive at least one of the plurality of renal catheters and can be sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch. Each of the plurality of peripheral catheter lumens can be sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch. In some cases, each of the plurality of renal catheter lumens and peripheral catheter lumens exit the
introducer sheath at distinct locations along a length of the sheath. In some cases, at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section.
[0041] In yet another aspect, embodiments of the present invention provide a system for delivering treatment to a renal artery and a peripheral artery. The system includes a plurality of renal catheters, a plurality of peripheral catheters, and an introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens. At least one of the renal catheters may include a distal bifurcation. Each of the plurality of renal catheter lumens can be configured to receive at least one of the plurality of renal catheters. Each of the plurality of peripheral catheter lumens can be configured to receive at least one of the plurality of peripheral catheters, hi some cases, at least one of the renal catheter lumens is separated from at least one of the peripheral catheter lumens by a flexible separator flap. Each of the plurality of renal catheter lumens and peripheral catheter lumens may exit the introducer sheath at distinct locations along a length of the sheath, hi some cases, at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens includes a variable cross-section.
[0042] hi another aspect, embodiments of the present invention include a method of delivering treatment to a renal artery and a peripheral artery. The method may include, for example, positioning an introducer sheath in an iliac artery, where the introducer sheath includes a plurality of renal catheter lumens and a plurality of peripheral catheter lumens. The method may also include advancing each of a plurality of renal catheters through a respective renal catheter lumen of the plurality of renal catheter lumens to a location at or near the renal artery. Further, the method may include advancing each of a plurality of peripheral catheters through a respective peripheral catheter lumen of the plurality of peripheral catheter lumens to a location at or near the peripheral artery, hi some cases, at least one of the renal catheter lumens is separated from at least one of the peripheral catheter lumens by a flexible separator flap. Each of the plurality of renal catheter lumens and peripheral catheter lumens may exit the introducer sheath at distinct locations along a length of the sheath, hi some cases, at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section. Optionally, the method may include providing a renal treatment via at least one of the plurality of renal catheters, providing a peripheral treatment via at least one of the plurality of peripheral catheters, or both. Relatedly, the method may include delivering a renal therapeutic agent via
at least one of the plurality of renal catheters. The renal therapeutic agent may improve kidney function, prevent kidney damage, or both.
BRIEF DESCRIPTION OF THE DRAWINGS [0043] FIGS. IA-I C illustrate a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
[0044] FIG. 2 illustrates a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
[0045] FIG. 3 depicts an introducer sheath according to embodiments of the present invention.
[0046] FIG. 4 depicts an introducer sheath according to embodiments of the present invention.
[0047] FIG. 5 depicts an introducer sheath according to embodiments of the present invention.
[0048] FIG. 6 depicts an introducer sheath according to embodiments of the present invention.
[0049] FIG. 7 depicts an introducer sheath according to embodiments of the present invention.
[0050] FIG. 8 depicts a renal catheter according to embodiments of the present invention.
[0051] FIG. 9 depicts a Y-hub assembly according to embodiments of the present invention.
[0052] FIG. 10 depicts a treatment sheath according to embodiments of the present invention.
[0053] FIG. 11 depicts a treatment sheath according to embodiments of the present invention.
[0054] FIG. 12 depicts a treatment sheath according to embodiments of the present invention.
[0055] FIG. 13 illustrates a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
[0056] FIG. 14 illustrates a system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
[0057] FIGS. 15-15C depict an introducer sheath according to embodiments of the present invention.
[0058] FIGS. 16A-16C illustrates an exemplary method of using system for delivering a renal treatment via a renal artery and a peripheral treatment via a peripheral artery according to embodiments of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0059] In some embodiments, a treatment sheath can be delivered over a guidewire through an introducer or main outer sheath to a site of renal artery cannulation. Once the guidewire is removed, the treatment catheter can be delivered through the treatment sheath. Upon delivery and deployment of the catheter branches, the treatment sheath can be retracted from the body to allow space for passage of the device used in peripheral intervention.
[0060] Turning now to the drawings, FIG. IA shows a system 100 for delivering treatment to a renal artery 10 and a peripheral artery 20 of a patient according to embodiments of the present invention. A peripheral artery may encompass, for example, an iliac artery 30, a femoral artery 40, and the like. System 100 includes a renal treatment system having a renal catheter 110, a peripheral treatment system having a peripheral catheter 120, and an introducer sheath 130. In some cases, a renal treatment system includes a renal treatment sheath. Similarly, a peripheral treatment system can include a peripheral treatment sheath. In this embodiment, introducer sheath extends from an insertion point 50 to an aortic bifurcation 60. Renal catheter 110 and peripheral catheter 120 can each exit introducer sheath 130 laterally and navigate toward their own respective delivery site For example, renal catheter 110 can exit introducer sheath 130 and travel through aorta 70 to the renal arteries 10. As shown in FIG. IB, in some embodiments an introducer sheath 130' can have a first lumen
132' configured to receive a renal catheter 110' and a second lumen 134', and a second lumen 134' configured to receive a peripheral catheter 120'. First lumen 132' and second lumen 134'
can be divided by a separator 133'. In some aspects, a separator may include a flexible separator flap. FIG. 1C depicts an introducer sheath 130" having a single lumen 136" configured to receive a renal catheter 110" and a peripheral catheter 120". In some cases, an introducer sheath can be sized to extend from an insertion point to an opening in the iliac artery. In related cases, an introducer sheath can be sized to extend from an insertion point to an aortic bifurcation.
[0061] An exemplary system 200 for delivering treatment to a renal artery 201 and a peripheral artery 202 is illustrated in FIG. 2. System 200 includes a renal catheter 210, a peripheral catheter 220, and an introducer sheath 230. Introducer sheath extends from an insertion point 205 across an aortic bifurcation 206 to a peripheral artery 202, which may be an iliac artery 203 or a femoral artery 204. Renal catheter 210 and peripheral catheter 220 can each exit introducer sheath 230 laterally and navigate toward their own respective delivery site. Introducer sheath 230 includes a first portion 232 configured to receive renal catheter 210 and peripheral catheter 220, and a second portion 234 configured to receive peripheral catheter 220. Introducer sheath also includes an exit port 236 through which renal catheter 210 can pass. Often, first portion 232 has a larger diameter than second portion 234. In some embodiments, renal catheter 210 has an outer diameter of about 1.5F and peripheral intervention system has an outer diameter or equivalent thereof of about 8F. Introducer sheath 230 passes through a first iliac artery and extends to curve toward the opposite iliac artery, which can facilitate a convenient navigation of the peripheral system. Exit port 236 may be disposed anywhere along the length of introducer sheath 230. As shown in this embodiment, exit port 236 is disposed at a location proximal to a distal exit 238 of sheath 230. Exit port 236 allows renal catheter 210 to exit introducer sheath 230 at or near aortic bifurcation 206.
[0062] FIG. 3 depicts an introducer sheath 330 having a proximal portion 332 and a distal portion 334. Proximal portion is coupled with a Y-hub 331. In some embodiments, proximal portion 332 can have an inner diameter within a range from about 9.5F to about 1OF, and distal portion 334 can have an inner diameter within a range from about 8F to about 8.5F. In related embodiments, proximal portion 332 can have an inner diameter within a range from about 7.5F to about 12F, and distal portion 334 can have an inner diameter within a range from about 5.5F to about 9.5F. Optionally, proximal portion 332 can have an inner diameter of about 8F, and distal portion 334 can have an inner diameter of about 7F. Introducer sheath 330 also includes an exit port 336 disposed at a transition portion 337 situated between
proximal portion 332 and distal portion 334. Exit port 336 can include an open aperture sized to receive elements of a treatment system, such as a catheter or a sheath.
[0063] As shown in FIG. 4, an introducer sheath 430 may include a coiling or coil 440. In some embodiments, a coil provides structural reinforcement to an introducer sheath. Introducer sheath 430 includes a first proximal portion 432, a second distal portion 434, and a transition portion 437 disposed therebetween. Transition portion 437 often defines a tapered shape or profile and includes an exit port 436. In a corresponding fashion, coil 440 includes a first portion 442, a second portion 444, and a transition portion 447 disposed therebetween. In some embodiments, coil 440 is wrapped at a first pitch at first portion 442 and second portion 444, and is wrapped at a second pitch at transition portion 447. The second pitch at transition portion 447 can be spaced sufficiently to allow enough space for exit port 436 to provide an aperture or opening in introducer sheath 430 without piercing the coil or traversing the path of the coil. Accordingly, the exit port can be created without disturbing the continuity of the coil, hi some cases, the transition portion 447 reflects a jump in the coil pitch for one full wrap. Coils may be disposed on an outside layer of the introducer sheath, on an inside layer of the introducer sheath, or on an intermediate layer of the introducer sheath.
[0064] In some embodiments, an introducer sheath may include a coil layer disposed only distal to the transition portion. FIG. 5 illustrates an introducer sheath 530 having a first portion 532, a second portion 534, and a tapered transition portion 537 disposed therebetween. Transition portion 537 may present an exit port 536. Introducer sheath 530 also includes a coil 540 disposed at or near second portion 534. m some cases, the wall thickness of first portion 532 may be greater than the wall thickness of second portion 534, as compensation for the torquability on the proximal and wider end of the first portion of the introducer sheath. Such configurations can help maintain a uniform or desired torquing profile along the length of introducer sheath 530.
[0065] As noted above with reference to FIG. 3, an exit port can have an open aperture through which a renal catheter or treatment sheath can pass. The exit port may or may not include a covering or plug. As shown in FIG. 6, an introducer sheath 630 can include a proximal portion 632, a distal portion 634, and a transition portion 637 disposed therebetween. Transition portion 637 includes an exit port 636 having a plug 636a with a passage slit 636b. In some embodiments, plug 636a includes an elastomeric material such as
silicone. Plug 636a can be formed in contour with the overall surface profile of the introducer sheath. Passage slit 636b can be sized to allow passage of elements of a renal treatment system, such as a renal treatment sheath or a renal catheter. Relatedly, FIG. 7 shows an introducer sheath 730 a proximal portion 732, a distal portion 734, and a transition portion 737 disposed therebetween. Transition portion 737 includes an exit port 736 having a plug 736a with a passage slit 736b. Plug 736a can be formed in contour with the overall surface profile of the introducer sheath. Passage slit 736b can be sized to allow passage of a renal catheter. In some embodiments, plug 736a includes one or more layers of elastomeric material. For example, plug 736a may include an inner layer 736c and an outer layer 736d. hi some cases, plug 736a includes an embedded inner silicone layer and an outer layer of low-durometer Pebax® covering the entire section circumferentially to aid in supporting the integrity of plug 736a.
[0066] Embodiments of the present invention provide various solutions for a functional back-end interface that can facilitate the delivery and retrieval of a renal treatment system, a peripheral treatment system, or both, in an integrated single stick system. FIG. 13 shows a system 1300 for delivering treatment to a renal artery and a peripheral artery. System 1300 includes a renal catheter 1310 and a peripheral catheter 1320. Renal catheter 1310 may include a proximal section 1312 disposed exterior to the patient's body, and a distal section 1314 disposed interior to the patient's body. Proximal section 1312 presents an extended or lengthened workable catheter length. Advantageously, the extended workable length of proximal section 1312 allows for facile treatment sheath removal without disruption of a fluid line, hi some embodiments, renal catheter 1310 includes a proximal section 1312 having a 1.5F NiTi section and a distal section 1314 having a 2-4F Pebax® section. The diameter of distal section 1314 can be selected so as to provide certain desired characteristics. For example, the distal section diameter can be selected to allow for decreased mechanical resistance to flow and for desired handling characteristics when a clinician or operator rolls or spools the workable length.
[0067] Other solutions for a functional back-end interface involve the removal of an treatment sheath from a catheter. Such solutions may or may not include catheters having an extended workable length. FIG. 9 illustrates an exemplary Y-hub 931 and introducer sheath 930 combination, wherein Y-hub is coupled with a proximal end 932 of introducer sheath 930. Y-hub 931 permits the entry of a renal treatment system and a peripheral treatment system therethrough. Y-hub can also act, often simultaneously, to allow infusion of a fluid
through a separate sub-port 931a. In some cases, sub-port 931a is in operative association with a Y-hub branch that receives a renal catheter. Optionally, sub-port 93 Ia can be in operative association with a Y-hub branch that receives a peripheral catheter. Ih some cases, a Y-hub may include such a sub-port on both Y-hub branches. Sub-port 93 Ia can be coupled or in fluid communication with an infusion pump 980, and can enter Y-hub 930 at an infusion insertion section thereof. Infusion insertion section 985 can be disposed or isolated within the Y-hub branch between two plugs 986. In the embodiment shown here, catheter 910 includes perforations or apertures 913 that allow passage of infusion fluid from sub-port 931a into catheter 910. A sub-port can be connected with an infusion pump, and can enter a renal catheter entry lumen of a Y-hub at a section that is isolated by two plugs. The plugs may allow for selective passage of a catheter or treatment sheath, but inhibit passage of fluids under certain pressures. For example, the plugs may allow for the passage of a catheter or treatment sheath, but may prevent passage of a fluid that is pressurized at 20psi or less. A catheter can include perforations configured for alignment between the two plugs, such that fluid supplied by a infusion pump can pressurize in a sub-chamber or infusion insertion section between the two plugs and enter the catheter through the perforations. Embodiments such as these allow for the infusion of fluid into a catheter while also permitting removal and reentry of a treatment sheath for both delivery and recapture of a treatment catheter and any branches or devices attached thereto.
[0068] FIG. 14 illustrates an exemplary back-end interface having a Y-hub 1431 in combination with an introducer sheath 1430, wherein Y-hub is coupled with a proximal end 1432 of introducer sheath 1430. Y-hub 1431 permits the entry of a renal treatment system 1410 and a peripheral treatment or intervention system 1420 therethrough. Renal treatment system 1410 may include a needle pierce section 1415 adapted to receive a needle 1417, which may be coupled with an infusion source 1482. Needle pierce section 1415 can be disposed along the renal treatment system at a location where the renal treatment system exits the patient's body. Thus, introducer sheath 1430 can be delivered having an infusion pump 1480 connected or in fluid communication with a proximal end of the renal treatment system or catheter. When removal of treatment sheath 1430 is desired or required, the renal catheter can be disconnected at a proximal end from infusion pump 1480, and infusion can resume or continue from needle pierce section 1415. Renal treatment system 1410 may include a proximal catheter 1412 that includes a NiTi shaft.
[0069] Other back-end interface solutions include treatment sheaths that can be removed from a catheter via a longitudinal dissection configuration. FIG. 12 shows a proximal portion 1232 of a treatment sheath 1230. Proximal portion 1232 may include a pierce groove 1232a and a tear-away grip 1332b. With this peel-away configuration, when a treatment sheath is retrieved it can be easily removed. As desired, a peel-away configuration may or may not be used on conjunction with a catheter having an extended or lengthened workable catheter length. FIG. 10 illustrates an treatment sheath 1030 having a longitudinal clip section 1030a that can be clipped off from and reclipped on to a catheter line. In some cases, longitudinal clip section presents a continuous clip along the length of treatment sheath 1030. FIG. 11 illustrates a treatment sheath 1130 having an array of serially arranged sheath sections 1130a having clips 1130b, where sheath sections 1130a are held in place by a supporting structure such as a wire 1130c.
[0070] Another back-end interface solution includes a catheter connector. For example, as shown in FIG. 8, renal treatment system 810 includes a catheter connector 819 than can allow disconnection and reconnection of a catheter proximal section 812 and a catheter distal section 814. Such disconnection and reconnection of the catheter line can provide for facile removal of a treatment sheath. As desired, such a configuration may or may not be used on conjunction with a catheter having an extended or lengthened workable catheter length.
[0071] A wide variety of variable lumen construction sheaths may be used. In some embodiments, an intervention system may include an introducer sheath with variable lumen construction that has the ability to serve asynchronously or synchronously as a conduit for multiple devices. Many traditional sheaths and catheters are constructed with a single lumen. Multi lumen catheters are also common (such as balloon catheters) and multi-lumen sheaths have likewise been described in, for example, U.S. Patent 4,769,005 and U.S. Patent Application No. 11/073,421 filed March 4, 2005, the entire disclosures of which are hereby incorporated by reference for all purposes.
[0072] In some embodiments, the present sheath may differ from known sheaths in that it can be designed to handle multiple products through its multiple lumens either simultaneously and/or at different times, and can be adapted with variable luminal cross sections to allow for passage of devices of multiple larger sizes through different lumens at different times during a given procedure.
[0073] While it is possible to insert multiple devices through a single-lumen design, a dual lumen or multiple lumen design can provide the advantages of separating the multiple devices to reduce the propensity for tangling and also allows fluid separation between the lumens to allow for more selective infusions if desired.
[0074] In some embodiments, the present sheath has multiple lumens with varying points of exit from the sheath designed to allow passage of multiple devices to remote regions of the vasculature simultaneously or at different times during the same procedure. As an example, a sheath can have an outer diameter (OD) similar to that of a standard, commercially available 1OF vascular introducer sheath. In a dual lumen construction sheath, wherein the lumens have variable cross-sections, two devices with crossing profiles of about 8F can pass through either lumen at different times, or, alternatively, a device up to 8F can pass through one lumen simultaneously with a device of up to about 2F in the other lumen. Combinations between these extremes are also contemplated (e.g., two 5F devices simultaneously).
[0075] In some embodiments, the present sheath can be constructed using a flexible and lubricious separator between the two luminal spaces, which can be easily displaced as needed when devices are passed. Specifically, this device can have application in the same setting as devices as described in previously incorporated U.S. Provisional Patent Application Nos. 60/725,756 filed October 11, 2005 and 60/742,579 filed December 5, 2005. In an exemplary case, the sheath can be constructed with a dedicated 2-lumen hub, each lumen feeding into a separate lumen of the sheath. The sheath can taper to the desired diameter (1OF in this example) with the separator flap creating the two lumens. In this example, one of the lumens ends more proximally than the other, as is desired by the intended use of the product, as illustrated in FIGS. 15-15C. Introducer sheath 1530 includes a proximal section 1532, a distal section 1534, and a tapered transition section 1537 disposed therebetween, as depicted in FIG. 15. Transition section 1537 includes an exit port 1536. Introducer sheath 1530 also includes a first lumen 1530a configured to receive renal treatment system and a second lumen 1530b configured to receive a peripheral treatment system. Proximal section 1532 and transition section 1537 include a separator 1530c that divides first lumen 1530a and second lumen 1530b. Distal section 1534 includes a single lumen construction, as shown in FIG. 15A. Transition section 1537 includes a dual lumen construction with variable luminal cross- section, as shown in FIG. 15B. The cross sections of the first and second lumens may vary by movement of the wall separating the two lumens. Proximal section 1532 includes a dual
lumen construction, where both lumens are "full size" to facilitate device entry, as shown in FIG. 15C. In some embodiments, separator 1530c includes a flexible separator flap.
[0076] In some embodiments, a treatment sheath can be delivered over a guidewire through an introducer or main outer sheath to a site of renal artery cannulation. Once the guidewire is removed, the treatment catheter can be delivered through the treatment sheath. Upon delivery and deployment of the catheter, the treatment sheath can be retracted from the body to allow space for passage of a sheath used in a peripheral intervention. For example, as shown in FIGS. 16A-C, a treatment system 1600 can include an introducer sheath 1630, a renal treatment system 1610, and a peripheral treatment system 1620. Introducer sheath 1630 includes a proximal section 1632, a distal section 1634, and a transition section 1637 disposed therebetween. Transition section 1637 includes an exit port 1636. Introducer sheath 1630 also includes a flexible or stretchable separator 1631 that divides a first lumen 1633 from a second lumen 1635. Because separator 1631 is flexible, stretchable, or otherwise deformable, separator 1631 can move so as to allow variability in the interior dimensions of first lumen 1633 and second lumen 1635. Accordingly, first lumen 1633 and second lumen 1635 can be referred to as variable lumens, or as lumens having variable cross- sections or profiles. Renal treatment system 1610 can include a renal treatment sheath 1612, a renal catheter 1614 having a bifurcated distal end 1616, and a renal sheath guidewire 1618. Peripheral treatment system 1620 can include a peripheral treatment sheath 1622, a peripheral catheter 1624, and a peripheral sheath guidewire 1628.
[0077] FIG. 16A illustrates a method step that involves advancing renal treatment sheath 1612 along a renal sheath guidewire 1618 toward a renal treatment location. Renal treatment sheath 1612 passes through first lumen 1633 of the proximal section 1632 of introducer sheath 1630, and out of exit port 1636. Renal catheter 1614 is advanced through or housed within the interior of renal treatment sheath 1612 in a constrained or undeployed configuration. In some cases, due to the cross-sectional diameter of renal treatment sheath 1612, the section of separator 1631 that is within proximal section 1632 is flexed, stretched, or otherwise displaced, so as to accommodate renal treatment sheath 1612. Often, this involves increasing the cross-section of first lumen 1633 while decreasing the cross-section of second lumen 1635. When renal treatment sheath 1612 is placed in the desired position, renal sheath guidewire 1618 can be retracted. FIG. 16B illustrates a method step that encompasses retracting renal treatment sheath 1612 and deploying bifurcated distal end 116 of renal catheter 1614. Thereafter, renal treatment sheath 1612 can be removed via any of a
variety of techniques as discussed elsewhere herein. FIG. 16C depicts a method step that involves advancing peripheral treatment sheath 1622 along a peripheral sheath guidewire 1628 toward a peripheral treatment location. Peripheral treatment sheath 1622 passes through second lumen 1635 of the proximal section 1632 and distal section 1634 of introducer sheath 1630, and out of distal port 1639. Peripheral catheter 1624 is advanced through or housed within the interior of peripheral treatment sheath 1622. In some cases, due to the cross-sectional diameter of peripheral treatment sheath 1622, the section of separator 1631 that is within proximal section 1632 is flexed, stretched, or otherwise displaced, so as to accommodate peripheral treatment sheath 1622, peripheral catheter 1624, or both. Often, this involves increasing the cross-section of second lumen 1635 while decreasing the cross- section of first lumen 1633. When peripheral treatment sheath 1622 is placed in the desired position, peripheral sheath guidewire 1628 can be retracted.
Claims
WHAT IS CLAIMED IS:
L A system for delivering treatment to a renal artery and a peripheral artery, the system comprising: a renal catheter; a peripheral catheter; and an introducer sheath having a first lumen and a second lumen; wherein the first lumen is configured to receive the renal catheter and is sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch, and the second lumen is configured to receive the peripheral catheter and is sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch.
2. The system according to claim 1, wherein at least one of the first lumen and the second lumen comprises a variable cross-section.
3. The system according to claim 1, wherein the introducer sheath comprises an exit port in communication with the first lumen.
4. The system according to claim 1, wherein the introducer sheath comprises a proximal section, a distal section, and a tapered section therebetween having an exit port.
5. The system according to claim 4, wherein the introducer sheath comprises a coil disposed at the proximal section, the distal section, and the tapered section, and the coil has a first pitch at the proximal and distal sections and a second pitch at the tapered section.
6. The system according to claim 4, wherein the exit port comprises a plug having a slit.
7. The system according to claim 1, further comprising a drug infusion source in operative association with the renal catheter.
8. A system for delivering treatment to a renal artery and a peripheral artery, the system comprising: a renal catheter having a distal bifurcation; a peripheral catheter; and an introducer sheath having a first lumen and a second lumen; wherein the first lumen is configured to receive the renal catheter and is separated from the second lumen by a flexible separator flap, and the second lumen is configured to receive the peripheral catheter.
9. The system according to claim 8, wherein at least one of the first lumen and the second lumen comprises a variable cross-section.
10. The system according to claim 8, wherein the introducer sheath comprises an exit port in communication with the first lumen.
11. The system according to claim 8, wherein the introducer sheath comprises a proximal section, a distal section, and a tapered section therebetween having an exit port.
12. The system according to claim 11, wherein the introducer sheath comprises a coil disposed at the proximal section, the distal section, and the tapered section, and the coil has a first pitch at the proximal and distal sections and a second pitch at the tapered section.
13. The system according to claim 8, further comprising a drug source in operative association with the renal catheter.
14. A method of delivering treatment to a renal artery and a peripheral artery, the method comprising: positioning an introducer sheath in an iliac artery; advancing a renal catheter through a first lumen of the introducer sheath to a location at or near the renal artery; and advancing a peripheral catheter through a second lumen of the introducer sheath to a location at or near the peripheral artery; wherein the first lumen and the second lumen of the introducer sheath are separated by a flexible separator flap.
15. The method according to claim 14, wherein at least one of the first lumen and the second lumen comprises a variable cross-section.
16. The method according to claim 14, further comprising advancing the renal catheter through an exit port of the introducer sheath, where the exit port is in communication with the first lumen.
17. The method according to claim 14, further comprising providing a renal treatment via the renal catheter, and providing a peripheral treatment via the peripheral catheter.
18. The method according to claim 14, further comprising delivering a renal therapeutic agent via the renal catheter, wherein the renal therapeutic agent improves kidney function, prevents kidney damage, or both.
19. A system for delivering treatment to a renal artery and a peripheral artery, the system comprising: a renal catheter; a peripheral catheter; and an introducer sheath having an exit port; wherein the introducer sheath is configured to receive the renal catheter and the peripheral catheter and is sized to extend from a patient insertion site past a femoral or iliac artery location near or distal to a patient aortic branch to an opposite femoral or iliac artery location near or distal to the patient aortic branch, such that when the introducer sheath is placed in the patient, the exit port is situated at or near the a femoral or iliac artery location near or distal to the patient aortic branch.
20. The system according to claim 18, wherein the introducer sheath comprises a proximal section, a distal section, a tapered section therebetween, and the exit port is disposed at the tapered section.
21. The system according to claim 19, wherein the introducer sheath comprises a coil disposed at the proximal section, the distal section, and the tapered section, and the coil has a first pitch at the proximal and distal sections and a second pitch at the tapered section.
22. The system according to claim 18, wherein the renal catheter comprises a bifurcated distal end.
23. A method of positioning a renal treatment system and a peripheral treatment system, the method comprising: positioning an introducer sheath in an iliac artery; advancing a renal catheter of the renal treatment system through a lumen of the introducer sheath to a location at or near a renal artery; and advancing a peripheral catheter of the peripheral treatment system through the lumen of the introducer sheath to a location at or near a peripheral artery.
24. The method according to claim 23, further comprising advancing the renal catheter through an exit port of the introducer sheath, wherein the exit port is located proximal to a distal end of the introducer sheath.
25. The method according to claim 23, further comprising providing a renal treatment via the renal catheter, and providing a peripheral treatment via the peripheral catheter.
26. The method according to claim 23, further comprising delivering a renal therapeutic agent via the renal catheter, wherein the renal therapeutic agent improves kidney function, prevents kidney damage, or both.
27. A system for delivering treatment to a renal artery and a peripheral artery, the system comprising: a plurality of renal catheters; a plurality of peripheral catheters; and an introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens; wherein each of the plurality of renal catheter lumens is configured to receive at least one of the plurality of renal catheters and is sized to extend from a patient insertion site to a femoral or iliac artery location near or distal to a patient aortic branch, and each of the plurality of peripheral catheter lumens is sized to extend from the patient insertion site to an opposite femoral or iliac artery location near or distal to the patient aortic branch.
28. The system according to claim 27, wherein each of the plurality of renal catheter lumens and peripheral catheter lumens exit the introducer sheath at distinct locations along a length of the sheath.
29. The system according to claim 27, wherein at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section.
30. A system for delivering treatment to a renal artery and a peripheral artery, the system comprising: a plurality of renal catheters, wherein at least one of the renal catheters comprises a distal bifurcation; a plurality of peripheral catheters; and an introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens; wherein each of the plurality of renal catheter lumens is configured to receive at least one of the plurality of renal catheters, each of the plurality of peripheral catheter lumens is configured to receive at least one of the plurality of peripheral catheters, and at least one of the renal catheter lumens is separated from at least one of the peripheral catheter lumens by a flexible separator flap.
31. The system according to claim 30, wherein each of the plurality of renal catheter lumens and peripheral catheter lumens exit the introducer sheath at distinct locations along a length of the sheath.
32. The system according to claim 30, wherein at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section.
33. A method of delivering treatment to a renal artery and a peripheral artery, the method comprising: positioning an introducer sheath in an iliac artery, the introducer sheath having a plurality of renal catheter lumens and a plurality of peripheral catheter lumens; advancing each of a plurality of renal catheters through a respective renal catheter lumen of the plurality of renal catheter lumens to a location at or near the renal artery; and advancing each of a plurality of peripheral catheters through a respective peripheral catheter lumen of the plurality of peripheral catheter lumens to a location at or near the peripheral artery; wherein at least one of the renal catheter lumens is separated from at least one of the peripheral catheter lumens by a flexible separator flap.
34. The method according to claim 33, wherein each of the plurality of renal catheter lumens and peripheral catheter lumens exit the introducer sheath at distinct locations along a length of the sheath.
35. The method according to claim 33, wherein at least one lumen of the plurality of renal catheter lumens and the plurality of peripheral catheter lumens comprises a variable cross-section.
36. The method according to claim 33, further comprising providing a renal treatment via at least one of the plurality of renal catheters, and providing a peripheral treatment via at least one of the plurality of peripheral catheters.
37. The method according to claim 33, further comprising delivering a renal therapeutic agent via at least one of the plurality of renal catheters, wherein the renal therapeutic agent improves kidney function, prevents kidney damage, or both.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06825915A EP1933920A4 (en) | 2005-10-11 | 2006-10-11 | Vascular sheath with variable lumen construction |
JP2008535713A JP2009511199A (en) | 2005-10-11 | 2006-10-11 | Vascular sheath with variable lumen configuration |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72575605P | 2005-10-11 | 2005-10-11 | |
US60/725,756 | 2005-10-11 | ||
US74257905P | 2005-12-05 | 2005-12-05 | |
US60/742,579 | 2005-12-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007044907A2 true WO2007044907A2 (en) | 2007-04-19 |
WO2007044907A3 WO2007044907A3 (en) | 2007-09-07 |
Family
ID=37943557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/040094 WO2007044907A2 (en) | 2005-10-11 | 2006-10-11 | Vascular sheath with variable lumen construction |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070167913A1 (en) |
EP (1) | EP1933920A4 (en) |
JP (1) | JP2009511199A (en) |
WO (1) | WO2007044907A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014072690A1 (en) * | 2012-11-08 | 2014-05-15 | Barking, Havering And Redbridge University Hospital National Health Service Trust | A device for introducing a medical element into a blood vessel |
US10166362B2 (en) | 2015-04-15 | 2019-01-01 | Sanford Health | Pulmonary embolism apparatus |
WO2019006158A3 (en) * | 2017-06-28 | 2019-03-07 | Abiomed, Inc. | Guidewire access sleeve |
CN113660973A (en) * | 2019-05-13 | 2021-11-16 | 美敦力瓦斯科尔勒公司 | Extended introducer for left radial access |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050197624A1 (en) | 2004-03-04 | 2005-09-08 | Flowmedica, Inc. | Sheath for use in peripheral interventions |
EP1435253B1 (en) | 2002-12-31 | 2007-01-17 | Abbott Laboratories Vascular Enterprises Limited | Catheter having a more flexible part between shaft and tip and method of manufacturing thereof |
US7815627B2 (en) * | 2004-05-27 | 2010-10-19 | Abbott Laboratories | Catheter having plurality of stiffening members |
US7785439B2 (en) * | 2004-09-29 | 2010-08-31 | Abbott Laboratories Vascular Enterprises Limited | Method for connecting a catheter balloon with a catheter shaft of a balloon catheter |
ATE442879T1 (en) * | 2004-05-27 | 2009-10-15 | Abbott Lab | CATHETER WITH FIRST AND SECOND GUIDE WIRE TUBE AND GAP IN BETWEEN |
US7658723B2 (en) * | 2004-05-27 | 2010-02-09 | Abbott Laboratories | Catheter having plurality of stiffening members |
US7794448B2 (en) * | 2004-05-27 | 2010-09-14 | Abbott Laboratories | Multiple lumen catheter and method of making same |
US7785318B2 (en) * | 2004-05-27 | 2010-08-31 | Abbott Laboratories | Catheter having plurality of stiffening members |
US7628769B2 (en) * | 2004-05-27 | 2009-12-08 | Abbott Laboratories | Catheter having overlapping stiffening members |
CN102516241B (en) * | 2006-05-19 | 2015-07-29 | 艾伯维巴哈马有限公司 | The azabicyclic alkane derivatives of the bicyclic heterocycle the condensed replacement of CNS activity |
US20090306625A1 (en) * | 2007-03-09 | 2009-12-10 | Angiodynamics, Inc. | Treatment systems and methods for renal-related diseases |
US20090076447A1 (en) * | 2007-09-19 | 2009-03-19 | Jack Casas | Method and apparatus for conducting peripheral vascular disease procedures using a novel anchor balloon catheter |
JP6039199B2 (en) * | 2012-03-12 | 2016-12-07 | 株式会社グッドマン | catheter |
US9439598B2 (en) | 2012-04-12 | 2016-09-13 | NeuroMedic, Inc. | Mapping and ablation of nerves within arteries and tissues |
JP5907027B2 (en) * | 2012-09-26 | 2016-04-20 | ニプロ株式会社 | catheter |
CN106659531A (en) | 2014-05-07 | 2017-05-10 | 毕达哥拉斯医疗有限公司 | Controlled tissue ablation techniques |
EP3157411B1 (en) * | 2014-06-19 | 2022-12-07 | Koninklijke Philips N.V. | Determining an effective cross-sectional area of a cardiovascular structure |
US9981119B2 (en) * | 2014-10-29 | 2018-05-29 | Edwards Lifesciences Corporation | Bi-directional cannula |
EP3226814A1 (en) | 2014-12-04 | 2017-10-11 | TriVascular, Inc. | Internal iliac preservation devices and methods |
US10383685B2 (en) | 2015-05-07 | 2019-08-20 | Pythagoras Medical Ltd. | Techniques for use with nerve tissue |
WO2017199240A2 (en) | 2016-05-18 | 2017-11-23 | Pythagoras Medical Ltd. | Helical catheter |
WO2018080470A1 (en) * | 2016-10-26 | 2018-05-03 | Medtronic, Inc. | Interventional medical systems and catheters |
US20210205595A1 (en) * | 2018-05-30 | 2021-07-08 | Palmaya Pty Ltd. | Fluid coupling |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US254236A (en) * | 1882-02-28 | phipps | ||
US53904A (en) * | 1866-04-10 | Improvement in steam hoisting apparatus | ||
US2499045A (en) * | 1948-08-16 | 1950-02-28 | Walker Frank Ray | Rectal dilator and medicator |
US3516408A (en) * | 1967-09-21 | 1970-06-23 | Vincent L Montanti | Arterial bypass |
US3667069A (en) * | 1970-03-27 | 1972-06-06 | Univ Minnesota | Jet pump cardiac replacement and assist device and method of at least partially replacing a disabled right heart |
US3730186A (en) * | 1971-03-05 | 1973-05-01 | Univ California | Adjustable implantable artery-constricting device |
US3791374A (en) * | 1971-08-09 | 1974-02-12 | Department Of Health Education | Programmer for segmented balloon pump |
US4248224A (en) * | 1978-08-01 | 1981-02-03 | Jones James W | Double venous cannula |
US4493697A (en) * | 1979-05-10 | 1985-01-15 | Krause Horst E | Method and apparatus for pumping blood within a vessel |
US4309994A (en) * | 1980-02-25 | 1982-01-12 | Grunwald Ronald P | Cardiovascular cannula |
US4423725A (en) * | 1982-03-31 | 1984-01-03 | Baran Ostap E | Multiple surgical cuff |
US4636195A (en) * | 1982-04-02 | 1987-01-13 | Harvey Wolinsky | Method and apparatus for removing arterial constriction |
SE455164B (en) * | 1985-12-05 | 1988-06-27 | Data Promeditech Inc Ab | PUMP FOR BIOLOGICAL SCIENCES |
IT8629545V0 (en) * | 1986-06-12 | 1986-06-12 | Fina Ernesto | SET BALLOON URETERAL CATHETER BALLOON FOR EXTRACTION OF URETERAL STONES |
DE3621350A1 (en) * | 1986-06-26 | 1988-01-14 | Bonzel Tassilo | DILATATION CATHETER WITH AN EXPANDABLE BALLOON |
US4723939A (en) * | 1986-07-31 | 1988-02-09 | The Research Foundation Of State Univ. Of New York | Apparatus and method for multiple organ procurement |
US4840172A (en) * | 1986-09-04 | 1989-06-20 | Augustine Scott D | Device for positioning an endotracheal tube |
US4990139A (en) * | 1986-09-10 | 1991-02-05 | Jang G David | Tandem independently inflatable/deflatable multiple diameter balloon angioplasty catheter systems |
US4753221A (en) * | 1986-10-22 | 1988-06-28 | Intravascular Surgical Instruments, Inc. | Blood pumping catheter and method of use |
US5002532A (en) * | 1987-01-06 | 1991-03-26 | Advanced Cardiovascular Systems, Inc. | Tandem balloon dilatation catheter |
US4925443A (en) * | 1987-02-27 | 1990-05-15 | Heilman Marlin S | Biocompatible ventricular assist and arrhythmia control device |
US4902272A (en) * | 1987-06-17 | 1990-02-20 | Abiomed Cardiovascular, Inc. | Intra-arterial cardiac support system |
US4834707A (en) * | 1987-09-16 | 1989-05-30 | Evans Phillip H | Venting apparatus and method for cardiovascular pumping application |
US4817586A (en) * | 1987-11-24 | 1989-04-04 | Nimbus Medical, Inc. | Percutaneous bloom pump with mixed-flow output |
IL85249A0 (en) * | 1988-01-29 | 1988-07-31 | Galram Technology Ind Ltd | Heart assist device |
US4906229A (en) * | 1988-05-03 | 1990-03-06 | Nimbus Medical, Inc. | High-frequency transvalvular axisymmetric blood pump |
US4909252A (en) * | 1988-05-26 | 1990-03-20 | The Regents Of The Univ. Of California | Perfusion balloon catheter |
US4964864A (en) * | 1988-09-27 | 1990-10-23 | American Biomed, Inc. | Heart assist pump |
US4919647A (en) * | 1988-10-13 | 1990-04-24 | Kensey Nash Corporation | Aortically located blood pumping catheter and method of use |
US5069662A (en) * | 1988-10-21 | 1991-12-03 | Delcath Systems, Inc. | Cancer treatment |
US4927412A (en) * | 1988-12-08 | 1990-05-22 | Retroperfusion Systems, Inc. | Coronary sinus catheter |
US4902291A (en) * | 1989-01-31 | 1990-02-20 | University Of Utah Research Foundation | Collapsible artificial ventricle and pumping shell |
US5087244A (en) * | 1989-01-31 | 1992-02-11 | C. R. Bard, Inc. | Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen |
US4927407A (en) * | 1989-06-19 | 1990-05-22 | Regents Of The University Of Minnesota | Cardiac assist pump with steady rate supply of fluid lubricant |
US4995864A (en) * | 1989-08-15 | 1991-02-26 | Imed Corporation | Dual chamber pumping apparatus |
US5318532A (en) * | 1989-10-03 | 1994-06-07 | C. R. Bard, Inc. | Multilumen catheter with variable cross-section lumens |
SE465017B (en) * | 1989-11-24 | 1991-07-15 | Lars Knutson | DEVICE FOR SEGMENTAL PERFUSION / ASPIRATION OF THE ENTREPRENEUR |
US5089019A (en) * | 1989-12-06 | 1992-02-18 | Medtronic, Inc. | Muscle work output monitor by intramuscular temperature variation measurement |
US5098442A (en) * | 1989-12-06 | 1992-03-24 | Medtronic, Inc. | Muscle contraction control by intramuscular pressure monitoring |
US5308319A (en) * | 1989-12-28 | 1994-05-03 | Sumitmo Bakelite Company Limited | Cardio assist system and insertion device therefor |
US5205810A (en) * | 1990-10-15 | 1993-04-27 | Medtronic, Inc. | Muscle powered cardiac assist system |
US5119804A (en) * | 1990-11-19 | 1992-06-09 | Anstadt George L | Heart massage apparatus |
US5308320A (en) * | 1990-12-28 | 1994-05-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Portable and modular cardiopulmonary bypass apparatus and associated aortic balloon catheter and associated method |
CA2104121C (en) * | 1991-04-24 | 1998-12-22 | Blair D. Walker | Exchangeable integrated-wire balloon catheter |
US5112301A (en) * | 1991-06-19 | 1992-05-12 | Strato Medical Corporation | Bidirectional check valve catheter |
US5180364A (en) * | 1991-07-03 | 1993-01-19 | Robert Ginsburg | Valved self-perfusing catheter guide |
US5282784A (en) * | 1991-10-09 | 1994-02-01 | Mentor Corporation | Injection stent system |
US5368566A (en) * | 1992-04-29 | 1994-11-29 | Cardiovascular Dynamics, Inc. | Delivery and temporary stent catheter having a reinforced perfusion lumen |
US5383840A (en) * | 1992-07-28 | 1995-01-24 | Vascor, Inc. | Biocompatible ventricular assist and arrhythmia control device including cardiac compression band-stay-pad assembly |
US5290227A (en) * | 1992-08-06 | 1994-03-01 | Pasque Michael K | Method of implanting blood pump in ascending aorta or main pulmonary artery |
US5336178A (en) * | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5292309A (en) * | 1993-01-22 | 1994-03-08 | Schneider (Usa) Inc. | Surgical depth measuring instrument and method |
ES2077519B1 (en) * | 1993-11-22 | 1996-07-01 | Fernandez De Lomana Euge Anaya | INTRAAORTIC CATHETER FOR RENAL PERFUSION AND CONSERVATION. |
US5397307A (en) * | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
US5613949A (en) * | 1994-04-01 | 1997-03-25 | Advanced Cardiovascular Systems, Inc. | Double balloon catheter assembly |
US5599306A (en) * | 1994-04-01 | 1997-02-04 | Localmed, Inc. | Method and apparatus for providing external perfusion lumens on balloon catheters |
US5484385A (en) * | 1994-04-21 | 1996-01-16 | C. R. Bard, Inc. | Intra-aortic balloon catheter |
US5762599A (en) * | 1994-05-02 | 1998-06-09 | Influence Medical Technologies, Ltd. | Magnetically-coupled implantable medical devices |
US5509428A (en) * | 1994-05-31 | 1996-04-23 | Dunlop; Richard W. | Method and apparatus for the creation of tricuspid regurgitation |
US5613980A (en) * | 1994-12-22 | 1997-03-25 | Chauhan; Tusharsindhu C. | Bifurcated catheter system and method |
US5609628A (en) * | 1995-04-20 | 1997-03-11 | Keranen; Victor J. | Intravascular graft and catheter |
US5713853A (en) * | 1995-06-07 | 1998-02-03 | Interventional Innovations Corporation | Methods for treating thrombosis |
DE19535781C2 (en) * | 1995-09-26 | 1999-11-11 | Fraunhofer Ges Forschung | Device for active flow support of body fluids |
JP2750569B2 (en) * | 1995-12-07 | 1998-05-13 | 幸夫 堀口 | Intravascular blood flow regulator and artificial blood vessel for bypass |
US6251133B1 (en) * | 1996-05-03 | 2001-06-26 | Medinol Ltd. | Bifurcated stent with improved side branch aperture and method of making same |
US5617878A (en) * | 1996-05-31 | 1997-04-08 | Taheri; Syde A. | Stent and method for treatment of aortic occlusive disease |
EP0820784B1 (en) * | 1996-07-24 | 2003-06-11 | Cordis Corporation | Balloon catheter and methods of use |
EP0835673A3 (en) * | 1996-10-10 | 1998-09-23 | Schneider (Usa) Inc. | Catheter for tissue dilatation and drug delivery |
US5902336A (en) * | 1996-10-15 | 1999-05-11 | Mirimedical, Inc. | Implantable device and method for removing fluids from the blood of a patient method for implanting such a device and method for treating a patient experiencing renal failure |
US5976178A (en) * | 1996-11-07 | 1999-11-02 | Vascular Science Inc. | Medical grafting methods |
US5916213A (en) * | 1997-02-04 | 1999-06-29 | Medtronic, Inc. | Systems and methods for tissue mapping and ablation |
US5720735A (en) * | 1997-02-12 | 1998-02-24 | Dorros; Gerald | Bifurcated endovascular catheter |
US6013054A (en) * | 1997-04-28 | 2000-01-11 | Advanced Cardiovascular Systems, Inc. | Multifurcated balloon catheter |
US5947953A (en) * | 1997-08-06 | 1999-09-07 | Hemocleanse, Inc. | Splittable multiple catheter assembly and methods of inserting the same |
US6889082B2 (en) * | 1997-10-09 | 2005-05-03 | Orqis Medical Corporation | Implantable heart assist system and method of applying same |
US6390969B1 (en) * | 1997-10-09 | 2002-05-21 | Orqis Medical Corporation | Implantable heart assist system and method of applying same |
US6387037B1 (en) * | 1997-10-09 | 2002-05-14 | Orqis Medical Corporation | Implantable heart assist system and method of applying same |
US6699231B1 (en) * | 1997-12-31 | 2004-03-02 | Heartport, Inc. | Methods and apparatus for perfusion of isolated tissue structure |
US5902229A (en) * | 1998-03-30 | 1999-05-11 | Cardio Technologies, Inc. | Drive system for controlling cardiac compression |
US6117117A (en) * | 1998-08-24 | 2000-09-12 | Advanced Cardiovascular Systems, Inc. | Bifurcated catheter assembly |
US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6749598B1 (en) * | 1999-01-11 | 2004-06-15 | Flowmedica, Inc. | Apparatus and methods for treating congestive heart disease |
US6884258B2 (en) * | 1999-06-04 | 2005-04-26 | Advanced Stent Technologies, Inc. | Bifurcation lesion stent delivery using multiple guidewires |
US6544279B1 (en) * | 2000-08-09 | 2003-04-08 | Incept, Llc | Vascular device for emboli, thrombus and foreign body removal and methods of use |
US6514226B1 (en) * | 2000-02-10 | 2003-02-04 | Chf Solutions, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney |
US6533747B1 (en) * | 2000-05-23 | 2003-03-18 | Chf Solutions, Inc. | Extracorporeal circuit for peripheral vein fluid removal |
US7604612B2 (en) * | 2001-05-01 | 2009-10-20 | St. Jude Medical, Cardiology Division, Inc. | Emboli protection devices and related methods of use |
GB0123633D0 (en) * | 2001-10-02 | 2001-11-21 | Angiomed Ag | Stent delivery system |
US7105016B2 (en) * | 2002-04-23 | 2006-09-12 | Medtronic Vascular, Inc. | Integrated mechanical handle with quick slide mechanism |
US6887258B2 (en) * | 2002-06-26 | 2005-05-03 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices for bifurcated vessels |
US7163520B2 (en) * | 2002-06-26 | 2007-01-16 | Chf Solutions, Inc. | Method and device for removal of radiocontrast media from blood |
US7232452B2 (en) * | 2002-07-12 | 2007-06-19 | Ev3 Inc. | Device to create proximal stasis |
ATE332163T1 (en) * | 2002-08-23 | 2006-07-15 | Medical Components Inc | CATHETER WITH SHIELDED TIP |
AU2003300779A1 (en) * | 2002-09-20 | 2004-05-04 | Flowmedica, Inc. | Catheter system for renal therapy |
WO2004026371A2 (en) * | 2002-09-20 | 2004-04-01 | Flowmedica, Inc. | Method and apparatus for selective drug infusion via an intraaortic flow diverter delivery catheter |
US7993325B2 (en) * | 2002-09-20 | 2011-08-09 | Angio Dynamics, Inc. | Renal infusion systems and methods |
US20050197624A1 (en) * | 2004-03-04 | 2005-09-08 | Flowmedica, Inc. | Sheath for use in peripheral interventions |
US20060069323A1 (en) * | 2004-09-24 | 2006-03-30 | Flowmedica, Inc. | Systems and methods for bi-lateral guidewire cannulation of branched body lumens |
US7491188B2 (en) * | 2004-10-12 | 2009-02-17 | Boston Scientific Scimed, Inc. | Reinforced and drug-eluting balloon catheters and methods for making same |
-
2006
- 2006-10-11 US US11/548,565 patent/US20070167913A1/en not_active Abandoned
- 2006-10-11 JP JP2008535713A patent/JP2009511199A/en not_active Withdrawn
- 2006-10-11 WO PCT/US2006/040094 patent/WO2007044907A2/en active Application Filing
- 2006-10-11 EP EP06825915A patent/EP1933920A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of EP1933920A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014072690A1 (en) * | 2012-11-08 | 2014-05-15 | Barking, Havering And Redbridge University Hospital National Health Service Trust | A device for introducing a medical element into a blood vessel |
US10166362B2 (en) | 2015-04-15 | 2019-01-01 | Sanford Health | Pulmonary embolism apparatus |
US10857326B2 (en) | 2015-04-15 | 2020-12-08 | Sanford Health | Pulmonary embolism apparatus |
US11766541B2 (en) | 2015-04-15 | 2023-09-26 | Sanford Health | Pulmonary embolism apparatus |
WO2019006158A3 (en) * | 2017-06-28 | 2019-03-07 | Abiomed, Inc. | Guidewire access sleeve |
US10953205B2 (en) | 2017-06-28 | 2021-03-23 | Abiomed, Inc. | Guidewire access sleeve |
CN113660973A (en) * | 2019-05-13 | 2021-11-16 | 美敦力瓦斯科尔勒公司 | Extended introducer for left radial access |
Also Published As
Publication number | Publication date |
---|---|
EP1933920A2 (en) | 2008-06-25 |
JP2009511199A (en) | 2009-03-19 |
US20070167913A1 (en) | 2007-07-19 |
EP1933920A4 (en) | 2010-12-29 |
WO2007044907A3 (en) | 2007-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070167913A1 (en) | Vascular sheath with variable lumen construction | |
US7914503B2 (en) | Method and apparatus for selective material delivery via an intra-renal catheter | |
US20060079859A1 (en) | Renal infusion systems and methods | |
US11801363B2 (en) | Slide guide catheter and methods for use thereof | |
US6994700B2 (en) | Apparatus and method for inserting an intra-aorta catheter through a delivery sheath | |
US7063679B2 (en) | Intra-aortic renal delivery catheter | |
US8585678B2 (en) | Method and apparatus for intra-aortic substance delivery to a branch vessel | |
US7766961B2 (en) | Systems and methods for performing bi-lateral interventions or diagnosis in branched body lumens | |
US5180364A (en) | Valved self-perfusing catheter guide | |
US20070142819A1 (en) | Bifurcated catheter for agent delivery and method of agent delivery | |
US20040103516A1 (en) | Intravascular device and method of manufacture and use | |
US20060030814A1 (en) | Method and apparatus for selective drug infusion via an intra-aortic flow diverter delivery catheter | |
JP2006508776A5 (en) | ||
WO2004107965A2 (en) | Systems and methods for performing bi-lateral interventions or diagnosis in branched body lumens | |
US20180064906A1 (en) | Method and Apparatus for Intra-Aortic Substance Delivery to a Branch Vessel | |
US20110190778A1 (en) | Multiple Port Introducer for Thrombolysis | |
WO2005002660A1 (en) | Method and apparatus for intra aortic substance delivery to a branch vessel | |
US20210085937A1 (en) | Multiple Entry, Single Lumen Dilator with a Delivery Sheath | |
US20220040447A1 (en) | Multi-Lumen Intravascular Catheters with inner Converging Lumens for Multiple Guidewire Control | |
WO2022115254A1 (en) | Vasculature navigation systems and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006825915 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008535713 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |